



Impact of anemia on clinical outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention: insights from the AFCAS registry

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-004700
Article Type:	Research
Date Submitted by the Author:	16-Dec-2013
Complete List of Authors:	Puurunen, Marja; Finnish Red Cross Blood Service, Laboratory of Hemostasis Kiviniemi, Tuomas; Turku University Hospital, Heart Center Nammass, Wail; Turku University Hospital, Heart Center Schlitt, Axel; Martin Luther University Halle-Wittenberg, Medical Faculty Rubboli, Andrea; Ospedale Maggiore, Division of Cardiology Nyman, Kai; Central Finland Central Hospital, Department of Cardiology Karjalainen, Pasi; Satakunta Central Hospital, Heart Center Kirchhof, Paulus; University of Birmingham, Centre for Cardiovascular Sciences Lip, Gregory; University Department of Medicine, Airaksinen, Juhani; Turku University Hospital, Heart Center
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Haematology (incl blood transfusion)
Keywords:	HAEMATOLOGY, CARDIOLOGY, Coronary intervention < CARDIOLOGY, Anaemia < HAEMATOLOGY, Anticoagulation < HAEMATOLOGY

1
2
3
4 **Impact of anemia on clinical outcome in patients with atrial fibrillation**
5
6 **undergoing percutaneous coronary intervention: insights from the AFCAS**
7
8 **registry**
9
10

11
12
13
14 **Puurunen Marja***, **Kiviniemi Tuomas†**, **Nammas Wail†**, **Schlitt Axel ‡**, **Rubboli**
15 **Andrea§**, **Nyman Kai#**, **Karjalainen Pasi¶**, **Kirchhof Paulus††,****, **Lip Gregory YH††**,
16
17 **Airaksinen KE Juhani†**
18
19

20
21 * Hemostasis laboratory, Finnish Red Cross Blood Service, Helsinki, Finland

22
23 †Heart Center, Turku University Hospital and University of Turku, Turku, Finland;

24
25 ‡Medical Faculty, Martin Luther University Halle-Wittenberg, Halle-Wittenberg, Germany;

26
27 §Division of Cardiology, Laboratory of Interventional Cardiology, Ospedale Maggiore,
28
29 Bologna, Italy;

30
31 #Department of Cardiology, Central Finland Central Hospital, Jyväskylä, Finland;

32
33 ¶Heart Center, Satakunta Central Hospital, Pori, Finland;

34
35 ** Department of Cardiovascular Medicine, Hospital of the University of Münster, Münster,
36
37 Germany

38
39 ††University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham,
40
41 United Kingdom

42
43 **Address for correspondence:** Dr. K. E. Juhani Airaksinen, Heart Center, Turku University
44
45 Hospital, Kiinamylynkatu 4-8, FIN-20520 Turku, Finland.

46
47 Email: juhani.airaksinen@tyks.fi

48
49 **Word count** (excluding title page, abstract, tables, figures and references) 2380
50
51

ABSTRACT

Background: Anemia has an adverse impact on the outcome of patients with percutaneous coronary intervention (PCI). The aim of this study was to analyze the impact of anemia on the 12-month clinical outcome of patients with atrial fibrillation (AF) undergoing PCI and therefore requiring intense antithrombotic treatment.

Methods: Data from the prospective, multicenter AFCAS (Atrial Fibrillation undergoing Coronary Artery Stenting) registry with AF patients undergoing PCI was analyzed. Anemia was defined as a hemoglobin concentration of <12 g/dl for women, and <13 g/dl for men. The primary endpoint was occurrence of major adverse cardiac and cerebrovascular events (MACCE) or bleeding events.

Results: A total of 861/929 (92.7%) patients had available preprocedural hemoglobin concentration, of whom 258 (30%) had anemia. Anemic patients were older, had more often diabetes, higher CHA₂DS₂-VASc score, prior history of heart failure, chronic renal impairment, and acute coronary syndrome. Anemic patients had more MACCE than non-anemic (29.1% versus 19.4%, respectively, $p=0.002$), and minor bleeding events (7.0% versus 3.3%, respectively, $p=0.028$), with a trend toward more total bleeding events (25.2% versus 21.7%, respectively, $p=0.059$). No difference was observed in antithrombotic regimens at discharge. In multivariate analysis anemia was an

1
2
3 independent predictor of all-cause mortality at 12-months follow-up (HR 1.62,
4
5 95% CI 1.05 – 2.51, p=0.029).
6
7

8 **Conclusions:** Anemia was a frequent finding in patients with AF referred for
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Conclusions: Anemia was a frequent finding in patients with AF referred for
PCI. Anemic patients had a higher all-cause mortality, more thrombotic events,
and minor bleeding events. Anemia seems to identify patients at risk for
cardiovascular events and death.

Keywords: atrial fibrillation, percutaneous coronary intervention, anemia

Strengths and limitations of the study:

- The strength of the study is the enrolment of consecutive patients with the only exclusion criteria being unwillingness/inability to participate in the study. In this sense the study population represents well real-world patients with AF referred for PCI.
- The study adds to our knowledge on the prevalence and impact of anemia in AF patients undergoing PCI and thus requiring combination antithrombotic medication. It shows that anemia is a frequent finding and that even mild anemia has an adverse impact on outcome.
- The current study has the inherent limitations of the observational study design, including individual risk-based decision making in treatment choices, which may introduce selection bias. Another possible

1
2
3 confounder is the heterogeneity of the AF population among the
4
5 participating centers and some differences in the periprocedural routines.
6
7

- 8
9 - The aetiology of anemia could not be systematically investigated and is
10
11 therefore out of the scope of this study.
12
13

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

INTRODUCTION

It is estimated that around 5% of patients undergoing percutaneous coronary intervention (PCI) need long-term oral anticoagulation (OAC) due to atrial fibrillation (AF).[1,2] Yet, the current recommendations on the management of antithrombotic treatment in patients with AF undergoing PCI and stenting are mainly derived from small studies, amounting to a weak level of evidence.[3,4] Moreover, the real-world management of patients on OAC undergoing PCI is variable, and only partially adherent to the current recommendations.[5]

Defined according to the World Health Organization (WHO), anemia has been reported to affect nearly 25% of patients undergoing PCI and stenting. Anemic patients undergoing PCI are generally older with more comorbidities, and have higher rates of in-hospital mortality and major adverse cardiac and cerebrovascular events (MACCE), as well as 1-year mortality.[6,7] Furthermore, low admission hemoglobin level was found to be an independent predictor of in-hospital and long-term mortality, and was associated with higher rates of in-hospital minor and major bleeding events in patients undergoing primary PCI for ST-segment elevation myocardial infarction (MI).[8,9]

However, little is known about the effect of anemia on the outcome of patients with AF undergoing PCI and thus requiring intensive antithrombotic treatment. This population is at high bleeding risk, which could be aggravated by the underlying anemia and its cause. Therefore, we analyzed data from the

1
2
3 prospective AFCAS (Atrial Fibrillation undergoing Coronary Artery Stenting)
4
5
6 registry to explore the impact of anemia on the 12-month clinical outcome of
7
8 patients with AF undergoing PCI.[10]
9

10 11 12 13 **METHODS**

14 15 **Patients**

16
17 The AFCAS registry (ClinicalTrials.gov number NCT00596570)
18
19 is a prospective, multicenter registry that enrolled patients with AF referred for
20
21 PCI in 5 European countries. The study design has been described in detail
22
23 previously.[11] Patients were enrolled if they had: 1) history of AF
24
25 (paroxysmal, persistent, or permanent), or 2) on-going AF during the index
26
27 PCI. Out of the 929 participants 861 (92.7%) had a preprocedural haemoglobin
28
29 count available and were included in this analysis.
30
31
32
33
34
35
36
37
38
39

40
41 Coronary angiography and PCI were performed via either radial or femoral
42
43 access, and hemostasis was achieved according to local practice. Coronary
44
45 lesions were treated according to contemporary interventional techniques. Low-
46
47 molecular-weight heparin (enoxaparin sodium, dalteparin), unfractionated
48
49 heparin, bivalirudin, and glycoprotein IIb/IIIa inhibitors were administered at
50
51 the operator's discretion. The post-discharge medication was completely at the
52
53 discretion of the treating physician.
54
55
56
57
58
59
60

1
2
3
4
5
6 The primary endpoints of the current study were 1) occurrence of MACCE
7
8 defined as a composite of all-cause mortality, any non-fatal MI, any
9
10 revascularization, definite/probable stent thrombosis, transient ischemic attack
11
12 (TIA) or stroke, and peripheral arterial embolism; 2) bleeding events; and 3)
13
14 total adverse events (a composite of MACCE plus bleeding events). Bleeding
15
16 events were defined according to the Bleeding Academic Research Consortium
17
18 (BARC) criteria as minor (BARC 2), and major (BARC 3a, 3b, 3c and 5)
19
20 bleeding events; however, CABG-related bleeding was excluded.[12] (Online
21
22 Table 1)
23
24
25
26
27
28
29
30
31

32 Anemia was defined as a hemoglobin concentration of <12 g/dl for women, and
33
34 <13 g/dl for men, according to the definition of the WHO.[13] Chronic renal
35
36 impairment was defined by an estimated glomerular filtration rate below 60
37
38 ml/min.
39
40
41
42
43
44

45 **Ethical aspects**

46
47
48 The study was initiated by the investigators and conducted according to the
49
50 ethical guidelines of the 1964 Declaration of Helsinki, as revised in 2002.
51
52
53 Informed written consent was obtained from every patient after full explanation
54
55
56
57
58
59
60

of the study protocol. The study protocol was approved by the ethics committees of the participating centers.

Statistical analysis

For analysis patients with available preprocedural measurement of hemoglobin concentration were divided into two subgroups: anemic patients, and control patients without anemia. Continuous variables were reported as the mean \pm standard deviation if normally distributed, and as median [inter-quartile range (IQR)] if they were skewed. Data were tested for normal distribution using the Kolmogorov-Smirnov and Shapiro-Wilk tests. Categorical variables were described with absolute and relative (percentage) frequencies. Comparisons between the two study subgroups were performed using the unpaired *t*-test or Mann-Whitney test for continuous variables, and Pearson χ^2 or Fisher's exact test for categorical variables, as appropriate. Cox regression hazard model was used to identify the independent predictors of MACCE, and all-cause mortality at 12-month follow-up. Variables strongly correlated with the dependent variable by univariate analyses were entered in the model as covariates. Likewise, Cox regression hazard model was used to identify the independent predictors of MACCE, and all-cause mortality at 12-month follow-up in the subgroup of anemic patients. Finally we constructed Kaplan-Meier survival curves to display the time-to-event relationship for the occurrence of all-cause

1
2
3 mortality, MACCE, and all bleeding events. Statistical analysis was performed
4
5 using SPSS statistical software (SPSS v. 16.0.1, SPSS Inc., Chicago, Ill., USA).
6
7
8
9

10 **RESULTS**

11 **Baseline characteristics**

12
13
14
15
16 Out of 929 patients enrolled in the AFCAS registry and followed up for 12
17
18 months, 861 (92.7%) had available preprocedural measurement of hemoglobin
19
20 concentration, of whom 258 (30%) had anemia and 603 (70%) had normal
21
22 hemoglobin concentration. Anemic patients were older, more likely to have
23
24 diabetes mellitus, hypertension, history of heart failure and chronic renal
25
26 impairment, HAS-BLED score ≥ 3 , higher CHA₂DS₂VASC score, and more
27
28 likely presented with acute coronary syndrome (ACS) as opposed to chronic
29
30 stable angina, compared with those without anemia ($p < 0.05$ for all), as shown
31
32 in Table 1. Furthermore, anemic patients had more vessels treated during the
33
34 index procedure, and a greater total stent length, compared with those without
35
36 anemia ($p < 0.05$ for both) (Table 2). At discharge, no significant differences
37
38 were seen in the prescription of antithrombotic medications in the two study
39
40 groups ($p = 0.15$) (Table 3). The duration of clopidogrel treatment did not differ
41
42 in anemic versus non-anemic patients on triple therapy (median [IQR]: 3 [11]
43
44 versus 3 [5] months, $p = 0.61$), on dual antiplatelet therapy (median [IQR]: 12
45
46 [11] versus 12 [11] months, $p = 0.72$), or on vitamin K antagonist + clopidogrel
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(median [IQR]: 12 [11] versus 3 [11] months, $p=0.65$). Proton pump inhibitors were more frequently prescribed to patients with anemia versus those without (47.7 versus 31.3%, respectively, $p < 0.001$).

Table 1 Baseline clinical characteristics of the two study subgroups

Variable	Anemia (N=258)	Non-anemic (N=603)	<i>p</i> value
Age (yrs)	76 [9]	73 [11]	<0.001
Female gender	89 (34.5)	170 (28.2)	0.074
Diabetes mellitus	119 (46.1)	191 (31.7)	<0.001
Hypercholesterolemia	162 (62.8)	407 (67.5)	0.183
Current or ex-smoking	26 (10.1)	62 (10.3)	1.00
Hypertension	221 (85.7)	503 (83.4)	0.48
Paroxysmal atrial fibrillation	103 (39.9)	229 (38.0)	0.594
Persistent atrial fibrillation	22 (8.5)	78 (12.9)	0.081
Permanent atrial fibrillation	129 (50)	294 (48.8)	0.766
CHA ₂ DS ₂ -VASc score >4	148 (57.4)	235 (39.0)	<0.001
HAS BLED score ≥ 3	215 (83.3)	441 (73.1)	0.001
History of peptic ulcer	17 (6.6)	27 (4.5)	0.236

History of cerebral hemorrhage	4 (1.6)	6 (1.0)	0.497
History of GI hemorrhage	9 (3.5)	12 (2.0)	0.144
History of heart failure	69 (26.7)	113 (18.7)	0.011
eGFR below 60 ml/min	119 (52.2)	175 (31.9)	<0.001
Prior transient ischemic attacks	12 (4.7)	30 (5.0)	1.00
Prior stroke	36 (14.0)	67 (11.1)	0.252
Prior MI	76 (29.5)	146 (24.2)	0.126
Prior PCI	47 (18.2)	100 (16.6)	0.555
Prior coronary bypass surgery	47 (18.2)	78 (12.9)	0.057
Proton pump inhibitors	123 (47.7)	189 (31.3)	<0.001
Stable angina pectoris	81 (31.4)	289 (48.0)	<0.001
ACS	177 (68.6)	313 (52.0)	<0.001
Unstable angina pectoris	53 (20.5)	107 (17.7)	0.34
Non-ST-elevation MI	83 (32.2)	132 (21.9)	0.002
ST-elevation MI	41 (15.9)	74 (12.3)	0.156

Continuous variables are presented as median [interquartile range], whereas categorical variables are presented as frequency (percentage).

ACS indicates acute coronary syndrome; eGFR, estimated glomerular filtration rate; GI, gastrointestinal, IQR, inter-quartile range; MI, myocardial infarction; PCI, percutaneous coronary intervention.

Table 2 Procedural data of the two study subgroups

Variable	Anemia (N=258)	Non-anemic (N=603)	<i>p</i> value
Femoral access	196 (76.0)	435 (72.1)	0.275
Number of treated vessels	1.22 ± 0.45	1.15 ± 0.41	0.04
DES	67 (27.0)	138 (23.6)	0.293
Peri-procedural INR	1.9 [1]	1.88 [1]	0.509
Stent diameter (mm)	3 [1]	3 [1]	0.965
Total stent length (mm)	20 [18]	19 [14]	0.014
Procedural success	252 (97.7)	582 (96.5)	0.085
Hemostasis			
Manual compression	112 (43.4)	249 (41.3)	0.765
Compression device ^a	49 (19.0)	155 (25.7)	0.083
Access-site closure device ^b	82 (31.8)	165 (27.4)	0.154

Continuous variables are presented as mean ± SD or median [interquartile range], whereas categorical variables are presented as frequency (percentage).

^aFemoStop[®], pneumatic compression device (Radi medical system, Sweden).

^bAngioseal[®], closure device (St. Jude medical, USA).

POBA indicates plain only balloon angioplasty, DES, drug-eluting stents; INR, international normalized ratio; IQR, inter-quartile range.

Table 3 Prescription of antithrombotic medications at discharge in the two study subgroups

Variable	Anemia (N=258)	Non-anemic (N=603)	<i>p</i> value
Triple therapy	181 (70.2)	442 (73.3)	0.15
DAPT	58 (22.5)	100 (16.6)	
VKA plus clopidogrel	15 (5.8)	51 (8.5)	
VKA plus aspirin	4 (1.6)	10 (1.7)	

Variables are presented as frequency (percentage).

*The number of patients available for follow-up of the duration of aspirin, clopidogrel, VKA was 258, 257, 159 in the group of anemia, and 600, 600, 402 in the control group, respectively.

VKA indicates vitamin K antagonist; DAPT, dual antiplatelet therapy.

Clinical outcome

Clinical outcomes at 12-month follow-up are presented in table 4 and figure 1.

The primary endpoint of MACCE was significantly more frequent in anemic patients than those without anemia (29.1 versus 19.4%, respectively, $p=0.002$).

This difference was driven by higher rates of all-cause mortality, non-fatal MI, and definite/probable ST ($p<0.05$ for all). Anemic patients had more BARC 3a bleeding events (7.0 versus 3.3%, respectively, $p=0.028$). No difference was seen in BARC 5 bleedings. There was a trend toward more total bleeding

events (25.2% in anemic versus 21.7% in controls, $p=0.059$). Total adverse events occurred more frequently in anemic versus non-anemic patients (43.0 versus 31.5%, respectively, $p=0.001$).

Table 4 Clinical outcome at 12-month follow-up in the two study subgroups

Endpoints	Anemia (N=258)	Non-anemic (N=603)	<i>p</i> value
MACCE	75 (29.1)	117 (19.4)	0.002
All-cause mortality	48 (18.6)	50 (8.3)	<0.001
Stroke/TIA	6 (2.3)	17 (2.8)	0.819
Peripheral arterial embolism	2 (0.8)	5 (0.8)	1.00
Non-fatal myocardial infarction	24 (9.3)	27 (4.5)	0.011
Any revascularization	19 (7.4)	51 (8.5)	0.683
Definite/probable stent thrombosis	10 (3.9)	4 (0.7)	0.002
Total bleeding events	65 (25.2)	131 (21.7)	0.059
Minor bleeding (BARC 2)	22 (8.5)	48 (8.0)	0.786
Major bleeding (BARC 3a, 3b, 3c, 5)	33 (12.8)	56 (9.3)	0.142
Total adverse events	111 (43.0)	190 (31.5)	0.001

Variables are presented as frequency (percentage).

MACCE indicates major adverse cardiac and cerebrovascular events; TIA, transient ischemic attacks; BARC, Bleeding Academic Research Consortium.

1
2
3 The incidence of definite/probable stent thrombosis was significantly higher in
4
5 anemic versus non-anemic patients (3.9 versus 0.7%, respectively, $p=0.002$).

6
7
8 Patients who developed stent thrombosis more often presented with ACS than
9
10 those who did not (80.0 versus 56.6%, respectively, $p=0.07$); however, the use
11
12 of triple therapy did not differ statistically between groups (60.0 versus 73.3%,
13
14 respectively, $p=0.25$).

15
16
17
18
19
20
21 In univariate analysis age above 75, diabetes, congestive heart failure, anemia,
22
23 chronic renal impairment, ACS at presentation, and total stent length were
24
25 strongly correlated with both MACCE and all-cause mortality at 12-month
26
27 follow-up. In the Cox regression model independent predictors of all-cause
28
29 mortality were anemia (HR 1.62, 95% CI 1.05 – 2.51, $p=0.029$), ACS at
30
31 presentation (HR 2.26, 95% CI 1.37 – 3.75, $p=0.001$), chronic renal impairment
32
33 (HR 2.35, 95% CI 1.52 – 3.65, $p<0.001$), and diabetes (HR 1.76, 95% CI 1.15 –
34
35 2.70, $p=0.009$). In contrast, anemia was not an independent predictor of
36
37 MACCE at 12-months follow-up unlike age above 75 years (HR 1.7, 95%-CI
38
39 1.2-2.4, $p=0.004$), diabetes (HR 1.7, 95%-CI 1.2-2.3, $p=0.002$), ACS at
40
41 presentation (HR 1.7, 95%-CI 1.2-2.3, $p=0.003$), and congestive heart failure
42
43 (HR 1.5, 95%-CI 1.0-2.1, $p=0.03$).

44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
When the anemic patients were analysed separately in the Cox
regression model, age over 75 years and ACS at presentation were identified as

1
2
3 independent predictors of MACCE at 12-months; and chronic renal
4
5
6 impairment, age over 75 years and ACS at presentation as independent
7
8
9 predictors of all-cause mortality

10
11 Among 861 patients with available preprocedural measurement of
12
13 haemoglobin concentration, 26 (2.8%) had severe anemia (defined as
14
15 haemoglobin below 10 g/dl). In this subgroup, MACCE occurred in 12 (46.2%)
16
17 patients, 10 (38.5%) patients died, and 8 (30.8%) experienced a BARC 2-5
18
19 bleeding episode. At discharge, triple therapy was prescribed in 18 (69.2%)
20
21 patients, dual anti-platelet therapy in 8 (30.8%), and no patient was prescribed
22
23 vitamin K antagonists plus a single anti-platelet drug. Proton pump inhibitors
24
25 were prescribed at discharge in 18 (69.2%) patients, and one (3.8%) patient had
26
27 a history of gastrointestinal bleeding.
28
29
30
31
32
33
34
35
36

37 **DISCUSSION**

38
39 Our study is the first report on the impact of anemia on the long-term clinical
40
41 outcome of patients with AF undergoing PCI. The AFCAS registry represent a
42
43 real-life cohort of high-risk AF-patients requiring PCI. The results of the
44
45 current study showing that 30% of the patients were anemic confirm the
46
47 previous reports that anemia is a frequent finding in real-world patients with
48
49 AF referred for PCI.[6-9,14] Anemic patients in the AFCAS registry were older
50
51
52
53
54
55
56
57
58
59
60

1
2
3 with more comorbidities, and presented more often with ACS, compared with
4
5 non-anemic patients, as also reported in previous cohorts.[6,7,9,14].
6
7

8
9
10
11 Overall, the 12-month clinical outcome was worse in anemic patients. Anemia
12
13 remained an independent predictor of all-cause mortality in multivariate
14
15 analysis. The higher rate of all-cause mortality might be related to the higher-
16
17 risk profile in anemic patients, as well as the underlying disease causing
18
19 anemia. Furthermore, anemic patients had more frequent MACCE at 12
20
21 months, primarily driven by higher rates of all-cause mortality, and non-fatal
22
23 MI. However, anemia was not an independent predictor of MACCE. The higher
24
25 rate of non-fatal MI might be explained, at least in part, by the higher frequency
26
27 of ACS at presentation in anemic patients.
28
29
30
31
32
33
34
35
36

37 The estimated thromboembolic risk of anemic patients according to CHADS₂
38
39 score was higher. However, no excess in TIA or stroke was seen during the
40
41 follow-up and only a trend towards more bleeding was observed. This is
42
43 contradictory to previous studies have reported a higher incidence of cardiac
44
45 and cerebrovascular thrombotic events at long-term follow-up in anemic versus
46
47 non-anemic patients in various patient cohorts referred for PCI.[7,9,14-18] The
48
49 relatively small number of complications in our patient cohort might explain
50
51 this difference.
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 The estimated bleeding risk according to the HAS-BLED score was higher in
7
8 anemic patients, but there was only a trend towards increased risk of major
9
10 bleeding. However, the results of the current study support the previous reports
11
12 on the increased bleeding risk associated with anemia in various patient groups
13
14 undergoing PCI.[8,9,19] Anemia may be a marker and consequence of an
15
16 underlying condition such as bleeding diathesis, occult gastrointestinal
17
18 bleeding, or malignancy that augments the bleeding risk. An interesting
19
20 observation is that neither the presence of anemia nor higher estimated bleeding
21
22 risk seemed to affect the clinician's choice of antithrombotic medications at
23
24 discharge. In view of our results, patients with anemia tolerated triple therapy
25
26 surprisingly well with only a trend towards increased bleeding.
27
28
29
30
31
32
33
34
35
36

37 We observed that the rate of definite or probable stent thrombosis was
38
39 significantly higher in anemic versus non-anemic patients ($p = 0.002$). ACS at
40
41 presentation may have contributed to the higher rate of stent thrombosis in
42
43 anemic patients, as patients with anemia more often presented with ACS versus
44
45 those without anemia. Consistent with our results, Pilgrim and co-workers,
46
47 observed a higher rate of definite stent thrombosis at 4-year follow-up in
48
49 anemic patients who underwent PCI with unrestricted use of drug-eluting
50
51 stents, compared with non-anemic ones.[14] Interestingly, in a recent study,
52
53
54
55
56
57
58
59
60

1
2
3 anemia was the only independent predictor of high residual platelet reactivity
4
5 on clopidogrel in a series of patients undergoing PCI.[20] These observations
6
7 warrant further studies to clarify the underlying mechanisms.
8
9

10
11
12
13 The effect of anemia on the clinical outcome of PCI appears early during
14 hospitalization. Kaplan-Meier event-free survival curves in the current study
15 revealed that most of the thrombotic as well as bleeding events occurred early
16 (within 30 days) following the index PCI (Figure 1). This finding is in line with
17 previous reports.[6,8,9,15] In patients with coronary artery disease, anemia
18 may aggravate myocardial ischemia, and unveil significant coronary
19 obstruction. Low hemoglobin levels might compromise myocardial oxygen
20 supply, particularly when it exceeds the autoregulatory capacity of coronary
21 flow reserve. Cardiac output increases in patients with anemia in order to
22 maintain adequate oxygen delivery to the tissues. This increases heart rate and
23 induces myocardial hypertrophy, which in turn, increases myocardial oxygen
24 demand, and further exaggerates the myocardial oxygen demand/supply
25 imbalance.[21] On the other hand, patients with severe anemia receive more
26 frequent blood transfusion, which was reported to have an adverse impact on
27 survival after PCI.[22] Unfortunately, information on blood transfusions was
28 not available in our registry. More importantly, anemia is frequently associated
29 with severe underlying chronic diseases which may compromise long-term
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 survival. Of note is a recent report suggesting that in patients who underwent
4
5
6 PCI with drug-eluting stents, those in whom anemia improved at follow-up had
7
8
9 less MACCE at a median follow-up of 25 months, compared with those with
10
11
12 sustained anemia suggesting that a transient cause is less detrimental than a
13
14
15 long-standing state causing anemia, e.g. malignancy.[16]
16
17
18

19 **Limitations of the study**

20
21 The current study has the inherent limitations of the observational study design,
22
23 including individual risk-based decision making in treatment choices, which
24
25
26 may introduce selection bias, even though we did not observe any difference
27
28
29 between the two study groups in the antithrombotic treatment prescribed at
30
31
32 discharge. Another possible confounder is the heterogeneity of the AF
33
34
35 population among the participating centers and some differences in the
36
37
38 periprocedural routines. Moreover, the aetiology of anemia was not
39
40
41 systematically investigated; yet, it is beyond the scope of the current study. The
42
43
44 strength of the study is the enrolment of consecutive patients with the only
45
46
47 exclusion criteria being unwillingness/inability to participate in the study. In
48
49
50 this sense the study population represents well real-world patients with AF
51
52
53 referred for PCI.
54
55
56
57
58
59
60

Conclusion

Anemia was a frequent finding in patients with AF referred for PCI. Anemic patients were older with more frequent comorbidities, and more often presented with ACS. Anemia seems to be an independent risk factor for all-cause mortality during 12-month follow-up. Anemia is also associated with more MACCE, and a trend toward a higher rate of bleeding.

ACKNOWLEDGMENTS

We thank our study coordinator Tuija Vasankari, RN, for her valuable input in data management.

COMPETING INTERESTS

The authors declare no competing interests.

CONTRIBUTORSHIP STATEMENT

Marja Puurunen and Tuomas Kiviniemi participated in data collection and analysis and writing the manuscript; Wail Nammas contributed to data analysis and writing of the manuscript; Axel Schlitt, Andrea Rubboli, Kai Nyman, Pasi Karjalainen and Paulus Kirchhof contributed to data collection and critical revision of the manuscript; Gregory Lip contributed to study design, data collection and critical revision of the manuscript; Juhani Airaksinen acted as

1
2
3 the primary investigator of the AFCAS study and contributed to study design,
4
5 data collection, data analysis and writing of the manuscript.
6
7

8 **FUNDING**

9
10
11 This study was supported by grants from the Finnish Foundation for
12
13 Cardiovascular Research, Helsinki, Finland.
14

15
16
17
18 **Extra data** is available by emailing Prof. Juhani Airaksinen at juhani.airaksinen@tyks.fi.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Rubboli A, Halperin JL, Airaksinen KE, et al. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. *Ann Med* 2008;40(6):428-36.
2. Rubboli A, Colletta M, Valencia J, et al for the WARfarin, Coronary STENTing (WAR-STENT) Study Group. Periprocedural management and in-hospital outcome of patients with indication for oral anticoagulation undergoing coronary artery stenting. *J Interv Cardiol* 2009;22:390–397.
3. Lip GYH, Huber K, Andreotti F, et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary—a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J* 2010;31:1311-1318.
4. Faxon DP, Eikelboom JW, Berger PB, et al. Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. *Thromb Haemost* 2011;106:522-84.

- 1
2
3 5. Rubboli A, Dewilde W, Huber K, et al. The management of patients on oral
4
5 anticoagulation undergoing coronary stent implantation: a survey among
6
7 interventional cardiologists from eight European countries. *J Interv Cardiol*
8
9 2012;25:163-9.
10
- 11
12
13 6. McKechnie RS, Smith D, Montoye C, et al; Blue Cross Blue Shield of
14
15 Michigan Cardiovascular Consortium (BMC2). Prognostic implication of
16
17 anemia on in-hospital outcomes after percutaneous coronary intervention.
18
19 *Circulation* 2004;110(3):271-7.
20
21
- 22
23
24 7. Nikolsky E, Mehran R, Aymong ED, et al. Impact of anemia on outcomes of
25
26 patients undergoing percutaneous coronary interventions. *Am J Cardiol*
27
28 2004;94(8):1023-7.
29
30
- 31
32
33 8. Dündar C, Oduncu V, Erkol A, et al. In-hospital prognostic value of
34
35 hemoglobin levels on admission in patients with acute ST segment elevation
36
37 myocardial infarction undergoing primary angioplasty. *Clin Res Cardiol*
38
39 2012;101(1):37-44.
40
41
- 42
43
44 9. Ayhan E, Aycicek F, Uyarel H, et al. Patients with anemia on admission
45
46 who have undergone primary angioplasty for ST elevation myocardial
47
48 infarction: in-hospital and long-term clinical outcomes. *Coron Artery Dis*
49
50 2011;22(6):375-9.
51
52
53
54
55
56
57
58
59
60

- 1
2
3 10. Kiviniemi T, Karjalainen P, Rubboli A, et al. Thrombocytopenia in patients
4
5 with atrial fibrillation on oral anticoagulation undergoing percutaneous
6
7 coronary intervention. *Am J Cardiol* 2013 Aug 15;112(4):493-8.
8
9
- 10
11 11. Schlitt A, Rubboli A, Lip GY, et al; for the AFCAS (Management of
12
13 patients with Atrial Fibrillation undergoing Coronary Artery Stenting Study
14
15 Group). The management of patients with atrial fibrillation undergoing
16
17 percutaneous coronary intervention with stent implantation: In-hospital-data
18
19 from the atrial fibrillation undergoing coronary artery stenting study.
20
21 *Catheter Cardiovasc Interv* 2013 Jun 13. doi: 10.1002/ccd.25064. [Epub
22
23 ahead of print]
24
25
26
27
28
- 29 12. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for
30
31 cardiovascular clinical trials: a consensus report from the bleeding academic
32
33 research consortium, *Circulation* 2011;123:2736-2747.
34
35
36
- 37 13. Nutritional anaemias. Report of a WHO scientific group. *World Health*
38
39 *Organ Tech* 1968;405:5-32.
40
41
- 42 14. Pilgrim T, Vetterli F, Kalesan B, et al. The impact of anemia on long-term
43
44 clinical outcome in patients undergoing revascularization with the
45
46 unrestricted use of drug-eluting stents. *Circ Cardiovasc Interv.*
47
48 2012;5(2):202-10.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 15.Lee PC, Kini AS, Ahsan C, et al. Anemia is an independent predictor of
4 mortality after percutaneous coronary intervention. *J Am Coll Cardiol.*
5
6 2004;44(3):541-6.
7
8
9
10
11 16.Kim TH, Koh YS, Chang K, et al; CathOlic university of Korea –
12 percutAneous Coronary inTervention registry investigators. Improved
13 anemia is associated with favorable long-term clinical outcomes in patients
14 undergoing PCI. *Coron Artery Dis* 2012;23(6):391-9.
15
16
17
18
19
20
21 17.Kitai Y, Ozasa N, Morimoto T, et al; on behalf of the CREDO-Kyoto
22 registry investigators. Prognostic implications of anemia with or without
23 chronic kidney disease in patients undergoing elective percutaneous
24 coronary intervention. *Int J Cardiol* 2013 Aug 16. doi:
25 10.1016/j.ijcard.2013.08.029.
26
27
28
29
30
31
32
33
34
35 18.Hosseini SK, Ansari MJ, Lotfi Tokaldany M, et al. Association between
36 preprocedural hemoglobin level and 1-year outcome of elective
37 percutaneous coronary intervention. *J Cardiovasc Med.* 2013 Feb 15. [Epub
38 ahead of print]
39
40
41
42
43
44
45 19.Manzano-Fernández S, Pastor FJ, Marín F, et al. Increased major bleeding
46 complications related to triple antithrombotic therapy usage in patients with
47 atrial fibrillation undergoing percutaneous coronary artery stenting. *Chest*
48 2008;134(3):559-67.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 20.Toma C, Zahr F, Moguilanski D, et al. Impact of anemia on platelet
4
5 response to clopidogrel in patients undergoing percutaneous coronary
6
7 stenting. *Am J Cardiol* 2012;109(8):1148-53.
8
9
10
11 21.Foley RN, Parfrey PS, Hamett JD, et al. The impact of anemia on
12
13 cardiomyopathy, morbidity, and mortality in end-stage renal disease. *Am J*
14
15 *Kidney Dis* 1996;28:53– 61.
16
17
18
19 22.Maluenda G, Lemesle G, Ben-Dor I, et al. Value of blood transfusion in
20
21 patients with a blood hematocrit of 24% to 30% after percutaneous coronary
22
23 intervention. *Am J Cardiol* 2009;104:1069 –1073.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FIGURE LEGENDS

Figure 1 Kaplan-Meier survival curves for the occurrence of adverse events in anemic (dotted lines) versus non-anemic (solid line) patients at 2-month follow-up: all-cause mortality (a), MACCE free survival (b) and bleeding event free survival (c)

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1 a
220x176mm (72 x 72 DPI)

ew only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1 b
220x176mm (72 x 72 DPI)

ew only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1 c
220x176mm (72 x 72 DPI)

ew only

Table 1. Bleeding Academic Research Consortium Definition for Bleeding.

Type 2	any overt, actionable sign of hemorrhage (eg, more bleeding than would be expected for a clinical circumstance, including bleeding found by imaging alone) that does not fit the criteria for type 3, 4, or 5 but does meet at least one of the following criteria: (1) requiring nonsurgical, medical intervention by a healthcare professional, (2) leading to hospitalization or increased level of care, or (3) prompting evaluation
Type 3a	Overt bleeding plus hemoglobin drop of 3 to 5 g/dL* (provided hemoglobin drop is related to bleed) Any transfusion with overt bleeding
Type 3b	Overt bleeding plus hemoglobin drop >5 g/dL* (provided hemoglobin drop is related to bleed) Cardiac tamponade Bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemorrhoid) Bleeding requiring intravenous vasoactive agents
Type 3c	Intracranial hemorrhage (does not include microbleeds or hemorrhagic transformation, does include intraspinal) Subcategories confirmed by autopsy or imaging or lumbar puncture Intraocular bleed compromising vision
Type 5	fatal bleeding

Type 1 and type 4 (coronary bypass related) bleeding events were not included in the analysis.

Online Table 2 Bleeding events at 12-month follow-up in the two study subgroups

Endpoints	Anemia (N=258)	Non-anemic (N=603)	<i>p</i> value
BARC 2	22 (8.5)	48 (8.0)	0.786
BARC 3a bleeding	18 (7.0)	20 (3.3)	0.028
BARC 3b bleeding	10 (3.9)	22 (3.6)	0.846
BARC 3c bleeding	0 (0)	9 (1.5)	0.064
BARC 5 bleeding	4 (1.6)	5 (0.8)	0.464
Total adverse events	111 (43.0)	190 (31.5)	0.001

Variables are presented as frequency (percentage).

BARC indicates Bleeding Academic Research Consortium.

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract ok (b) Provide in the abstract an informative and balanced summary of what was done and what was found ok
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported ok
Objectives	3	State specific objectives, including any prespecified hypotheses ok
Methods		
Study design	4	Present key elements of study design early in the paper ok
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection ok
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up ok (b) For matched studies, give matching criteria and number of exposed and unexposed
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable ok
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why ok
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding ok (b) Describe any methods used to examine subgroups and interactions ok (c) Explain how missing data were addressed ok (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed ok (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders ok (b) Indicate number of participants with missing data for each variable of interest ok (c) Summarise follow-up time (eg, average and total amount) ok
Outcome data	15*	Report numbers of outcome events or summary measures over time ok
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included ok

		(b) Report category boundaries when continuous variables were categorized ok
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses ok
Discussion		
Key results	18	Summarise key results with reference to study objectives ok
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias ok
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence ok
Generalisability	21	Discuss the generalisability (external validity) of the study results ok
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based ok

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

BMJ Open

Impact of anemia on clinical outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention: insights from the AFCAS registry

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-004700.R1
Article Type:	Research
Date Submitted by the Author:	20-Mar-2014
Complete List of Authors:	Puurunen, Marja; Finnish Red Cross Blood Service, Laboratory of Hemostasis Kiviniemi, Tuomas; Turku University Hospital, Heart Center Nammass, Wail; Turku University Hospital, Heart Center Schlitt, Axel; Martin Luther University Halle-Wittenberg, Medical Faculty Rubboli, Andrea; Ospedale Maggiore, Division of Cardiology Nyman, Kai; Central Finland Central Hospital, Department of Cardiology Karjalainen, Pasi; Satakunta Central Hospital, Heart Center Kirchhof, Paulus; University of Birmingham, Centre for Cardiovascular Sciences Lip, Gregory; University Department of Medicine, Airaksinen, Juhani; Turku University Hospital, Heart Center
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Haematology (incl blood transfusion)
Keywords:	HAEMATOLOGY, CARDIOLOGY, Coronary intervention < CARDIOLOGY, Anaemia < HAEMATOLOGY, Anticoagulation < HAEMATOLOGY

SCHOLARONE™
Manuscripts

1
2
3
4 **Impact of anemia on clinical outcome in patients with atrial fibrillation**
5
6 **undergoing percutaneous coronary intervention: insights from the AFCAS**
7
8 **registry**
9
10

11
12
13
14 **Puurunen Marja***, **Kiviniemi Tuomas†**, **Nammas Wail†**, **Schlitt Axel ‡**, **Rubboli**
15 **Andrea§**, **Nyman Kai#**, **Karjalainen Pasi¶**, **Kirchhof Paulus††,****, **Lip Gregory YH††**,
16
17 **Airaksinen KE Juhani†**
18
19

20
21 * Hemostasis laboratory, Finnish Red Cross Blood Service, Helsinki, Finland

22 †Heart Center, Turku University Hospital and University of Turku, Turku, Finland;

23 ‡Medical Faculty, Martin Luther University Halle-Wittenberg, Halle-Wittenberg, Germany;

24 §Division of Cardiology, Laboratory of Interventional Cardiology, Ospedale Maggiore,
25 Bologna, Italy;

26 #Department of Cardiology, Central Finland Central Hospital, Jyväskylä, Finland;

27 ¶Heart Center, Satakunta Central Hospital, Pori, Finland;

28 ** Department of Cardiovascular Medicine, Hospital of the University of Münster, Münster,
29 Germany
30

31 ††University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham,
32 United Kingdom
33

34
35 **Address for correspondence:** Dr. K. E. Juhani Airaksinen, Heart Center, Turku University
36 Hospital, Kiinamylynkatu 4-8, FIN-20520 Turku, Finland.
37

38 Email: juhani.airaksinen@tyks.fi
39

40 **Word count** (excluding title page, abstract, tables, figures and references) 2725
41
42
43
44
45
46
47
48
49
50
51

1
2
3 **Contributorship statement:** Marja Puurunen and Tuomas Kiviniemi participated in data
4 collection and analysis and writing the manuscript; Wail Nammas contributed to data analysis
5 and writing of the manuscript; Axel Schlitt, Andrea Rubboli, Kai Nyman, Pasi Karjalainen
6 and Paulus Kirchhof contributed to data collection and critical revision of the manuscript;
7 Gregory Lip contributed to study design, data collection and critical revision of the
8 manuscript; Juhani Airaksinen acted as the primary investigator of the AFCAS study and
9 contributed to study design, data collection, data analysis and writing of the manuscript.
10
11
12
13
14
15
16
17
18
19
20

21 **Extra data** is available by emailing Prof. Juhani Airaksinen at juhani.airaksinen@tyks.fi.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives: Anemia has an adverse impact on the outcome in the general patient population undergoing percutaneous coronary intervention (PCI). The aim of this study was to analyze the impact of anemia on the 12-month clinical outcome of patients with atrial fibrillation (AF) undergoing PCI and therefore requiring intense antithrombotic treatment. We hypothesized that anemia might be associated with a worse outcome and more bleeding in these anticoagulated patients.

Setting: Data was collected from 17 secondary care centers in Europe.

Participants: Consecutive patients with AF undergoing PCI were enrolled in the prospective, multicenter AFCAS (Atrial Fibrillation undergoing Coronary Artery Stenting) registry. Altogether 929 patients participated in the study. Preprocedural haemoglobin concentration was available for 861 (92.7%) (30% female). Only exclusion criteria were inability or unwillingness to give informed consent. Anemia was defined as a haemoglobin concentration of <12 g/dl for women, and <13 g/dl for men.

Outcome measures: The primary endpoint was occurrence of major adverse cardiac and cerebrovascular events (MACCE) or bleeding events.

Results: 258/861 (30%) patients had anemia. Anemic patients were older, had more often diabetes, higher CHA₂DS₂-VASc score, prior history of heart

1
2
3 failure, chronic renal impairment, and acute coronary syndrome. Anemic
4
5 patients had more MACCE than non-anemic (29.1% versus 19.4%,
6
7 respectively, $p=0.002$), and minor bleeding events (7.0% versus 3.3%,
8
9 respectively, $p=0.028$), with a trend toward more total bleeding events (25.2%
10
11 versus 21.7%, respectively, $p=0.059$). No difference was observed in
12
13 antithrombotic regimens at discharge. In multivariate analysis anemia was an
14
15 independent predictor of all-cause mortality at 12-months follow-up (HR 1.62,
16
17 95% CI 1.05 – 2.51, $p=0.029$).
18
19
20
21
22
23

24 **Conclusions:** Anemia was a frequent finding in patients with AF referred for
25
26 PCI. Anemic patients had a higher all-cause mortality, more thrombotic events,
27
28 and minor bleeding events. Anemia seems to identify patients at risk for
29
30 cardiovascular events and death.
31
32
33

34
35 **Trial registration:** ClinicalTrials.gov number NCT00596570
36
37
38
39

40 **Keywords:** atrial fibrillation, percutaneous coronary intervention, anemia
41
42
43
44
45

46 **Strengths and limitations of the study:**

- 47
48 - The strength of the study is the enrolment of consecutive patients with
49
50 the only exclusion criteria being unwillingness/inability to participate in
51
52 the study. In this sense the study population represents well real-world
53
54 patients with AF referred for PCI.
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- The study adds to our knowledge on the prevalence and impact of anemia in AF patients undergoing PCI and thus requiring combination antithrombotic medication. It shows that anemia is a frequent finding and that even mild anemia has an adverse impact on outcome.
 - The current study has the inherent limitations of the observational study design, including individual risk-based decision making in treatment choices, which may introduce selection bias. Another possible confounder is the heterogeneity of the AF population among the participating centers and some differences in the periprocedural routines.
 - The aetiology of anemia could not be systematically investigated and is therefore out of the scope of this study.

INTRODUCTION

It is estimated that around 5% of patients undergoing percutaneous coronary intervention (PCI) need long-term oral anticoagulation (OAC) due to atrial fibrillation (AF).[1,2] Yet, the current recommendations on the management of antithrombotic treatment in patients with AF undergoing PCI and stenting are mainly derived from small studies, amounting to a weak level of evidence.[3,4] Moreover, the real-world management of patients on OAC undergoing PCI is variable, and only partially adherent to the current recommendations.[5]

Defined according to the World Health Organization (WHO), anemia has been reported to affect nearly 25% of patients undergoing PCI and stenting. Anemic patients undergoing PCI are generally older with more comorbidities, and have higher rates of in-hospital mortality and major adverse cardiac and cerebrovascular events (MACCE), as well as 1-year mortality.[6,7] Furthermore, low admission haemoglobin level was found to be an independent predictor of in-hospital and long-term mortality, and was associated with higher rates of in-hospital minor and major bleeding events in patients undergoing primary PCI for ST-segment elevation myocardial infarction (MI).[8,9]

However, little is known about the effect of anemia on the outcome of patients with AF undergoing PCI and thus requiring intensive antithrombotic treatment. Anemia is possibly a marker of high bleeding risk, which could be aggravated by the underlying cause. Therefore, we analyzed data from the

1
2
3 prospective AFCAS (Atrial Fibrillation undergoing Coronary Artery Stenting)
4
5
6 registry to explore the impact of anemia on the 12-month clinical outcome of
7
8 patients with AF undergoing PCI.[10]
9

10 11 12 13 **METHODS**

14 15 **Patients**

16
17 The AFCAS registry (ClinicalTrials.gov number NCT00596570)
18
19 is a prospective, multicenter registry that enrolled patients with AF referred for
20
21 PCI in 5 European countries. The study design has been described in detail
22
23 previously.[11] Patients were enrolled if they had: 1) history of AF
24
25 (paroxysmal, persistent, or permanent), or 2) on-going AF during the index
26
27 PCI. Out of the 929 participants 861 (92.7%) had a preprocedural haemoglobin
28
29 count available and were included in this analysis.
30
31
32
33
34
35
36
37
38
39

40
41 Coronary angiography and PCI were performed via either radial or femoral
42
43 access, and hemostasis was achieved according to local practice. Coronary
44
45 lesions were treated according to contemporary interventional techniques. Low-
46
47 molecular-weight heparin (enoxaparin sodium, dalteparin), unfractionated
48
49 heparin, bivalirudin, and glycoprotein IIb/IIIa inhibitors were administered at
50
51 the operator's discretion. The post-discharge medication was completely at the
52
53 discretion of the treating physician.
54
55
56
57
58
59
60

1
2
3
4
5
6 The primary endpoints of the current study were 1) occurrence of MACCE
7
8 defined as a composite of all-cause mortality, any non-fatal MI, any
9
10 revascularization, definite/probable stent thrombosis, transient ischemic attack
11
12 (TIA) or stroke, and peripheral arterial embolism; 2) bleeding events; and 3)
13
14 total adverse events (a composite of MACCE plus bleeding events). Bleeding
15
16 events were defined according to the Bleeding Academic Research Consortium
17
18 (BARC) criteria as minor (BARC 2), and major (BARC 3a, 3b, 3c and 5)
19
20 bleeding events; however, CABG-related bleeding was excluded.[12] (Online
21
22 Table 1)
23
24
25
26
27
28
29
30
31

32 Anemia was defined as a haemoglobin concentration of <12 g/dl for women,
33
34 and <13 g/dl for men, according to the definition of the WHO.[13] Chronic
35
36 renal impairment was defined by an estimated glomerular filtration rate below
37
38 60 ml/min.
39
40
41
42
43
44

45 **Ethical aspects**

46
47
48 The study was initiated by the investigators and conducted according to the
49
50 ethical guidelines of the 1964 Declaration of Helsinki, as revised in 2002.
51
52
53 Informed written consent was obtained from every patient after full explanation
54
55
56
57
58
59
60

1
2
3 of the study protocol. The study protocol was approved by the ethics
4
5 committees of the participating centers.
6
7
8
9

10 11 **Statistical analysis**

12
13 For analysis patients with available preprocedural measurement of haemoglobin
14
15 concentration were divided into two subgroups: anemic patients, and control
16
17 patients without anemia. Continuous variables were reported as the mean \pm
18
19 standard deviation if normally distributed, and as median [inter-quartile range
20
21 (IQR)] if they were skewed. Data were tested for normal distribution using the
22
23 Kolmogorov-Smirnov and Shapiro-Wilk tests. Categorical variables were
24
25 described with absolute and relative (percentage) frequencies. Comparisons
26
27 between the two study subgroups were performed using the unpaired *t*-test or
28
29 Mann-Whitney test for continuous variables, and Pearson χ^2 or Fisher's exact
30
31 test for categorical variables, as appropriate. Cox regression hazard model was
32
33 used to identify the independent predictors of MACCE, and all-cause mortality
34
35 at 12-month follow-up. Baseline variables correlating at $p < 0.10$ level with the
36
37 dependent variable in univariate analyses were entered in the Cox regression
38
39 model as covariates. Cox regression hazard model was used to identify the
40
41 independent predictors of MACCE, and all-cause mortality at 12-month follow-
42
43 up in the subgroup of anemic patients. Finally we constructed Kaplan-Meier
44
45 survival curves to display the time-to-event relationship for the occurrence of
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 all-cause mortality, MACCE, and all bleeding events. Statistical analysis was
4
5 performed using SPSS statistical software (SPSS v. 16.0.1, SPSS Inc., Chicago,
6
7 Ill., USA).
8
9

10 11 12 13 **RESULTS**

14 **Baseline characteristics**

15
16
17
18
19 Out of 929 patients enrolled in the AFCAS registry and followed up for 12
20
21 months, 861 (92.7%) had available preprocedural measurement of haemoglobin
22
23 concentration, of whom 258 (30%) had anemia and 603 (70%) had normal
24
25 haemoglobin concentration. Anemic patients were older, more likely to have
26
27 diabetes mellitus, hypertension, history of heart failure and chronic renal
28
29 impairment, HAS-BLED score ≥ 3 , higher CHA₂DS₂VASC score, and more
30
31 likely presented with acute coronary syndrome (ACS) as opposed to chronic
32
33 stable angina, compared with those without anemia ($p < 0.05$ for all), as shown
34
35 in Table 1. Furthermore, anemic patients had more vessels treated during the
36
37 index procedure, and a greater total stent length, compared with those without
38
39 anemia ($p < 0.05$ for both) (Table 2). At discharge, no significant differences
40
41 were seen in the prescription of antithrombotic medications in the two study
42
43 groups ($p = 0.15$) (Table 3). The duration of clopidogrel treatment did not differ
44
45 in anemic versus non-anemic patients on triple therapy (median [IQR]: 3 [11]
46
47 versus 3 [5] months, $p = 0.61$), on dual antiplatelet therapy (median [IQR]: 12
48
49
50
51
52
53
54
55
56
57
58
59
60

[11] versus 12 [11] months, $p=0.72$), or on vitamin K antagonist + clopidogrel (median [IQR]: 12 [11] versus 3 [11] months, $p=0.65$). Proton pump inhibitors were more frequently prescribed to patients with anemia versus those without (47.7 versus 31.3%, respectively, $p < 0.001$).

Table 1 Baseline clinical characteristics of the two study subgroups

Variable	Anemia (N=258)	Non-anemic (N=603)	<i>p</i> value
Age (yrs)	76 [9]	73 [11]	<0.001
Female gender	89 (34.5)	170 (28.2)	0.074
Diabetes mellitus	119 (46.1)	191 (31.7)	<0.001
Hypercholesterolemia	162 (62.8)	407 (67.5)	0.183
Current or ex-smoking	26 (10.1)	62 (10.3)	1.00
Hypertension	221 (85.7)	503 (83.4)	0.48
Paroxysmal atrial fibrillation	103 (39.9)	229 (38.0)	0.594
Persistent atrial fibrillation	22 (8.5)	78 (12.9)	0.081
Permanent atrial fibrillation	129 (50)	294 (48.8)	0.766

1				
2				
3				
4	CHA ₂ DS ₂ -VASc score >4	148 (57.4)	235 (39.0)	<0.001
5				
6	HAS BLED score ≥3	215 (83.3)	441 (73.1)	0.001
7				
8				
9	History of peptic ulcer	17 (6.6)	27 (4.5)	0.236
10				
11				
12	History of cerebral hemorrhage	4 (1.6)	6 (1.0)	0.497
13				
14				
15	History of GI hemorrhage	9 (3.5)	12 (2.0)	0.144
16				
17				
18	History of heart failure	69 (26.7)	113 (18.7)	0.011
19				
20				
21	eGFR below 60 ml/min	119 (52.2)	175 (31.9)	<0.001
22				
23				
24	Prior transient ischemic attacks	12 (4.7)	30 (5.0)	1.00
25				
26				
27				
28	Prior stroke	36 (14.0)	67 (11.1)	0.252
29				
30				
31	Prior MI	76 (29.5)	146 (24.2)	0.126
32				
33				
34	Prior PCI	47 (18.2)	100 (16.6)	0.555
35				
36				
37	Prior coronary bypass surgery	47 (18.2)	78 (12.9)	0.057
38				
39				
40	Proton pump inhibitors	123 (47.7)	189 (31.3)	<0.001
41				
42				
43	Stable angina pectoris	81 (31.4)	289 (48.0)	<0.001
44				
45				
46	ACS	177 (68.6)	313 (52.0)	<0.001
47				
48				
49	Unstable angina pectoris	53 (20.5)	107 (17.7)	0.34
50				
51				
52	Non-ST-elevation MI	83 (32.2)	132 (21.9)	0.002
53				
54				
55	ST-elevation MI	41 (15.9)	74 (12.3)	0.156
56				
57				
58				
59				
60				

Continuous variables are presented as median [interquartile range], whereas categorical variables are presented as frequency (percentage).

ACS indicates acute coronary syndrome; eGFR, estimated glomerular filtration rate; GI, gastrointestinal, IQR, inter-quartile range; MI, myocardial infarction; PCI, percutaneous coronary intervention.

Table 2 Procedural data of the two study subgroups

Variable	Anemia (N=258)	Non-anemic (N=603)	<i>p</i> value
Femoral access	196 (76.0)	435 (72.1)	0.275
Number of treated vessels	1.22 ± 0.45	1.15 ± 0.41	0.04
DES	67 (27.0)	138 (23.6)	0.293
Peri-procedural INR	1.9 [1]	1.88 [1]	0.509
Stent diameter (mm)	3 [1]	3 [1]	0.965
Total stent length (mm)	20 [18]	19 [14]	0.014
Procedural success	252 (97.7)	582 (96.5)	0.085
Hemostasis			
Manual compression	112 (43.4)	249 (41.3)	0.765
Compression device ^a	49 (19.0)	155 (25.7)	0.083
Access-site closure device ^b	82 (31.8)	165 (27.4)	0.154

Continuous variables are presented as mean \pm SD or median [interquartile range], whereas categorical variables are presented as frequency (percentage).

^aFemoStop[®], pneumatic compression device (Radi medical system, Sweden).

^bAngioseal[®], closure device (St. Jude medical, USA).

DES, drug-eluting stents; INR, international normalized ratio; IQR, inter-quartile range.

Table 3 Prescription of antithrombotic medications at discharge in the two study subgroups

Variable	Anemia (N=258)	Non-anemic (N=603)	<i>p</i> value
Triple therapy	181 (70.2)	442 (73.3)	
DAPT	58 (22.5)	100 (16.6)	0.15
VKA plus clopidogrel	15 (5.8)	51 (8.5)	
VKA plus aspirin	4 (1.6)	10 (1.7)	

Variables are presented as frequency (percentage).

VKA indicates vitamin K antagonist; DAPT, dual antiplatelet therapy.

Clinical outcome

Clinical outcomes at 12-month follow-up are presented in table 4 and figure 1.

The primary endpoint of MACCE was significantly more frequent in anemic patients than those without anemia (29.1 versus 19.4%, respectively, $p=0.002$).

This difference was driven by higher rates of all-cause mortality, non-fatal MI, and definite/probable ST ($p<0.05$ for all). Anemic patients had more BARC 3a bleeding events (7.0 versus 3.3%, respectively, $p=0.028$). No difference was

1
2
3 seen in BARC 5 bleedings. There was a trend toward more total bleeding
4
5 events (25.2% in anemic versus 21.7% in controls, $p=0.059$). (For detailed
6
7 information on bleeding events see Online Table 2.) Total adverse events
8
9 occurred more frequently in anemic versus non-anemic patients (43.0 versus
10
11 31.5%, respectively, $p=0.001$).
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 4 Clinical outcome at 12-month follow-up in the two study subgroups

Endpoints	Anemia (N=258)	Non-anemic (N=603)	p value
MACCE	75 (29.1)	117 (19.4)	0.002
All-cause mortality	48 (18.6)	50 (8.3)	<0.001
Stroke/TIA	6 (2.3)	17 (2.8)	0.819
Peripheral arterial embolism	2 (0.8)	5 (0.8)	1.00
Non-fatal myocardial infarction	24 (9.3)	27 (4.5)	0.011
Any revascularization	19 (7.4)	51 (8.5)	0.683
Definite/probable stent thrombosis	10 (3.9)	4 (0.7)	0.002
Total bleeding events	65 (25.2)	131 (21.7)	0.059
Minor bleeding (BARC 2)	22 (8.5)	48 (8.0)	0.786
Major bleeding (BARC 3a, 3b, 3c, 5)	33 (12.8)	56 (9.3)	0.142
Access site complications	25 (9.7)	49 (8.1)	0.51
Pseudoaneurysm	7 (2.7)	18 (3.0)	1.0
Red blood cell transfusion	10 (3.9)	5 (0.9)	0.002
Need for corrective surgery	5 (1.9)	8 (1.3)	0.25
Prolonged hospitalization	15 (5.8)	23 (3.8)	0.21
Total adverse events	111 (43.0)	190 (31.5)	0.001

Variables are presented as frequency (percentage).

MACCE indicates major adverse cardiac and cerebrovascular events; TIA, transient ischemic attacks; BARC, Bleeding Academic Research Consortium.

1
2
3 The incidence of definite/probable stent thrombosis was significantly higher in
4 anemic versus non-anemic patients (3.9 versus 0.7%, respectively, $p=0.002$).
5
6 Patients who developed stent thrombosis more often presented with ACS than
7
8 those who did not (80.0 versus 56.6%, respectively, $p=0.07$); however, the use
9
10 of triple therapy did not differ statistically between groups (60.0 versus 73.3%,
11
12 respectively, $p=0.25$). Overall, nearly half (46.7%) of ST events occurred early
13
14 (<30 days). Acute (<24h after index PCI); early (<30 days) and late ST (>30
15
16 and < 365 days) were detected in 1 (0.4%) and 1 (0.2%) ($p=0.51$); 4 (1.6%) vs.
17
18 2 (0.3%) ($p=0.07$); and 6 (2.3%) vs. 2 (0.3%) ($p=0.01$) in patients with anemia
19
20 vs. those without anemia, respectively.
21
22
23
24
25
26
27
28
29
30
31

32 In univariate analysis age above 75, diabetes, congestive heart failure, anemia,
33
34 chronic renal impairment, ACS at presentation, and total stent length were
35
36 strongly correlated with both MACCE and all-cause mortality at 12-month
37
38 follow-up. In the Cox regression model including all the above variables,
39
40 independent predictors of all-cause mortality were anemia (HR 1.62, 95% CI
41
42 1.05 – 2.51, $p=0.029$), ACS at presentation (HR 2.26, 95% CI 1.37 – 3.75,
43
44 $p=0.001$), chronic renal impairment (HR 2.35, 95% CI 1.52 – 3.65, $p<0.001$),
45
46 and diabetes (HR 1.76, 95% CI 1.15 – 2.70, $p=0.009$). In contrast, anemia as a
47
48 categorical variable was not an independent predictor of MACCE at 12-months
49
50 follow-up unlike age above 75 years (HR 1.7, 95%-CI 1.2-2.4, $p=0.004$),
51
52
53
54
55
56
57
58
59
60

1
2
3 diabetes (HR 1.7, 95%-CI 1.2-2.3, p=0.002), ACS at presentation (HR 1.7,
4
5 95%-CI 1.2-2.3, p=0.003), and congestive heart failure (HR 1.5, 95%-CI 1.0-
6
7 2.1, p=0.03).

8
9
10 We performed the multivariate model also using haemoglobin as a continuous
11
12 variable. Independent predictors of all-cause mortality were pre-procedural
13
14 haemoglobin (HR 0.82, 95% CI 0.72 – 0.93, p=0.002), ACS at presentation
15
16 (HR 2.07, 95% CI 1.25 – 3.45, p=0.005), chronic renal impairment (HR 2.06,
17
18 95% CI 1.31 – 3.24, p=0.002), and diabetes (HR 1.75, 95% CI 1.14 – 2.70,
19
20 p=0.01) in a Cox regression model including age over 75 years, total stent
21
22 length and number of treated vessels as covariates. On the contrary to what
23
24 was found when assessing anemia as a categorical variable, haemoglobin as a
25
26 continuous variable predicted also MACCE. Independent predictors of
27
28 MACCE were pre-procedural haemoglobin (HR 0.89, 95% CI 0.81 – 0.98,
29
30 p=0.016), ACS at presentation (HR 1.55, 95% CI 1.10 – 2.18, p=0.012),
31
32 congestive heart failure (HR 1.45, 95% CI 1.03 – 2.04, p=0.035), age over 75
33
34 years (HR 1.77, 95%CI 1.27 – 2.45, p=0.001) and diabetes (HR 1.55, 95% CI
35
36 1.13 – 2.13, p=0.007) in a Cox regression model including also total stent
37
38 length, chronic renal impairment and number of treated vessels as covariates.
39
40
41
42
43
44
45
46
47
48
49

50
51 When the anemic patients were analysed separately in the Cox
52
53 regression model, age over 75 years and ACS at presentation were identified as
54
55 independent predictors of MACCE at 12-months; and chronic renal
56
57
58
59
60

1
2
3 impairment, age over 75 years and ACS at presentation as independent
4
5 predictors of all-cause mortality
6
7

8
9 Among 861 patients with available preprocedural measurement of
10
11 haemoglobin concentration, 26 (2.8%) had severe anemia (defined as
12
13 haemoglobin below 10 g/dl). In this subgroup, MACCE occurred in 12 (46.2%)
14
15 patients, 10 (38.5%) patients died, and 8 (30.8%) experienced a BARC 2-5
16
17 bleeding episode. At discharge, triple therapy was prescribed in 18 (69.2%)
18
19 patients, dual anti-platelet therapy in 8 (30.8%), and no patient was prescribed
20
21 vitamin K antagonists plus a single anti-platelet drug. Proton pump inhibitors
22
23 were prescribed at discharge in 18 (69.2%) patients, and one (3.8%) patient had
24
25 a history of gastrointestinal bleeding.
26
27
28
29
30
31
32
33
34

35 **DISCUSSION**

36
37 Our study is the first report on the impact of anemia on the long-term clinical
38
39 outcome of patients with AF undergoing PCI. The AFCAS registry represent a
40
41 real-life cohort of high-risk AF-patients requiring PCI. The results of the
42
43 current study showing that 30% of the patients were anemic confirm the
44
45 previous reports that anemia is a frequent finding in real-world patients with
46
47 AF referred for PCI.[6-9,14] Anemic patients in the AFCAS registry were older
48
49 with more comorbidities, and presented more often with ACS, compared with
50
51 non-anemic patients, as also reported in previous cohorts.[6,7,9,14].
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 Overall, the 12-month clinical outcome was worse in anemic patients. Anemia
7
8 remained an independent predictor of all-cause mortality in multivariate
9
10 analysis. The higher rate of all-cause mortality might be related to the higher-
11
12 risk profile in anemic patients, as well as the underlying disease causing
13
14 anemia. Furthermore, anemic patients had more frequent MACCE at 12
15
16 months, primarily driven by higher rates of all-cause mortality, and non-fatal
17
18 MI. However, anemia was not an independent predictor of MACCE. The higher
19
20 rate of non-fatal MI might be explained, at least in part, by the higher frequency
21
22 of ACS at presentation in anemic patients.
23
24
25
26
27
28
29
30
31

32 The estimated thromboembolic risk of anemic patients according to CHADS₂
33
34 score was higher. However, no excess in TIA or stroke was seen during the
35
36 follow-up and only a trend towards more bleeding was observed. This is
37
38 contradictory to previous studies have reported a higher incidence of cardiac
39
40 and cerebrovascular thrombotic events at long-term follow-up in anemic versus
41
42 non-anemic patients in various patient cohorts referred for PCI.[7,9,14-18] The
43
44 relatively small number of complications in our patient cohort might explain
45
46 this difference.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The estimated bleeding risk according to the HAS-BLED score was higher in
4
5 anemic patients, but there was only a trend towards increased risk of major
6
7 bleeding. However, the results of the current study support the previous reports
8
9 on the increased bleeding risk associated with anemia in various patient groups
10
11 undergoing PCI.[8,9,19] Anemia may be a marker and consequence of an
12
13 underlying condition such as bleeding diathesis, occult gastrointestinal
14
15 bleeding, or malignancy that augments the bleeding risk. An interesting
16
17 observation is that neither the presence of anemia nor higher estimated bleeding
18
19 risk seemed to affect the clinician's choice of antithrombotic medications at
20
21 discharge. In view of our results, patients with anemia tolerated triple therapy
22
23 surprisingly well with only a trend towards increased bleeding.
24
25
26
27
28
29
30
31
32
33

34
35 We observed that the rate of definite or probable stent thrombosis was
36
37 significantly higher in anemic versus non-anemic patients ($p = 0.002$). ACS at
38
39 presentation may have contributed to the higher rate of stent thrombosis in
40
41 anemic patients, as patients with anemia more often presented with ACS versus
42
43 those without anemia. Consistent with our results, Pilgrim and co-workers,
44
45 observed a higher rate of definite stent thrombosis at 4-year follow-up in
46
47 anemic patients who underwent PCI with unrestricted use of drug-eluting
48
49 stents, compared with non-anemic ones.[14] Interestingly, in a recent study,
50
51 anemia was the only independent predictor of high residual platelet reactivity
52
53
54
55
56
57
58
59
60

1
2
3 on clopidogrel in a series of patients undergoing PCI.[20] These observations
4
5 warrant further studies to clarify the underlying mechanisms.
6
7
8
9

10
11 The effect of anemia on the clinical outcome of PCI appears early during
12
13 hospitalization. Kaplan-Meier event-free survival curves in the current study
14
15 revealed that most of the thrombotic as well as bleeding events occurred early
16
17 (within 30 days) following the index PCI (Figure 1). This finding is in line with
18
19 previous reports.[6,8,9,15] In patients with coronary artery disease, anemia
20
21 may aggravate myocardial ischemia, and unveil significant coronary
22
23 obstruction. Cardiac output increases in patients with anemia in order to
24
25 maintain adequate oxygen delivery to the tissues. This increases heart rate and
26
27 induces myocardial hypertrophy, which in turn, increases myocardial oxygen
28
29 demand, and further exaggerates the myocardial oxygen demand/supply
30
31 imbalance.[21] On the other hand, patients with severe anemia receive more
32
33 frequent blood transfusion, which was reported to have an adverse impact on
34
35 survival after PCI.[22] Unfortunately, information on blood transfusions was
36
37 not available in our registry except for the in-hospital phase. More importantly,
38
39 anemia is frequently associated with severe underlying chronic diseases which
40
41 may compromise long-term survival. Of note is a recent report suggesting that
42
43 in patients who underwent PCI with drug-eluting stents, those in whom anemia
44
45 improved at follow-up had less MACCE at a median follow-up of 25 months,
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 compared with those with sustained anemia suggesting that a transient cause is
4
5 less detrimental than a long-standing state causing anemia, e.g. malignancy.[16]
6
7
8
9

10 **Limitations of the study**

11
12 The current study has the inherent limitations of the observational study design,
13
14 including individual risk-based decision making in treatment choices, which
15
16 may introduce selection bias, even though we did not observe any difference
17
18 between the two study groups in the antithrombotic treatment prescribed at
19
20 discharge. Another possible confounder is the heterogeneity of the AF
21
22 population among the participating centers and some differences in the
23
24 periprocedural routines. Moreover, the aetiology of anemia was not
25
26 systematically investigated; yet, it is beyond the scope of the current study. The
27
28 strength of the study is the enrolment of consecutive patients with the only
29
30 exclusion criteria being unwillingness/inability to participate in the study. In
31
32 this sense the study population represents well real-world patients with AF
33
34 referred for PCI.
35
36
37
38
39
40
41
42
43
44
45
46
47

48 **Conclusion**

49
50 Anemia was a frequent finding in patients with AF referred for PCI. Anemic
51
52 patients were older with more frequent comorbidities, and more often presented
53
54 with ACS. Anemia seems to be an independent risk factor for all-cause
55
56
57
58
59
60

1
2
3 mortality during 12-month follow-up. Anemia is also associated with more
4
5
6 MACCE, and a trend toward a higher rate of bleeding.
7
8
9

10 11 **ACKNOWLEDGMENTS**

12
13
14 We thank our study coordinator Tuija Vasankari, RN, for her valuable input in
15
16 data management.
17
18
19

20 21 **COMPETING INTERESTS**

22
23
24 The authors declare no competing interests.
25
26
27
28
29

30 31 **FUNDING**

32
33 This study was supported by grants from the Finnish Foundation for
34
35 Cardiovascular Research, Helsinki, Finland.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Rubboli A, Halperin JL, Airaksinen KE, et al. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. *Ann Med* 2008;40(6):428-36.
2. Rubboli A, Colletta M, Valencia J, et al for the WARfarin, Coronary STENTing (WAR-STENT) Study Group. Periprocedural management and in-hospital outcome of patients with indication for oral anticoagulation undergoing coronary artery stenting. *J Interv Cardiol* 2009;22:390–397.
3. Lip GYH, Huber K, Andreotti F, et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary—a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J* 2010;31:1311-1318.
4. Faxon DP, Eikelboom JW, Berger PB, et al. Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. *Thromb Haemost* 2011;106:522-84.

- 1
2
3 5. Rubboli A, Dewilde W, Huber K, et al. The management of patients on oral
4
5 anticoagulation undergoing coronary stent implantation: a survey among
6
7 interventional cardiologists from eight European countries. *J Interv Cardiol*
8
9 2012;25:163-9.
10
- 11
12
13 6. McKechnie RS, Smith D, Montoye C, et al; Blue Cross Blue Shield of
14
15 Michigan Cardiovascular Consortium (BMC2). Prognostic implication of
16
17 anemia on in-hospital outcomes after percutaneous coronary intervention.
18
19 *Circulation* 2004;110(3):271-7.
20
21
- 22
23
24 7. Nikolsky E, Mehran R, Aymong ED, et al. Impact of anemia on outcomes of
25
26 patients undergoing percutaneous coronary interventions. *Am J Cardiol*
27
28 2004;94(8):1023-7.
29
30
- 31
32
33 8. Dündar C, Oduncu V, Erkol A, et al. In-hospital prognostic value of
34
35 hemoglobin levels on admission in patients with acute ST segment elevation
36
37 myocardial infarction undergoing primary angioplasty. *Clin Res Cardiol*
38
39 2012;101(1):37-44.
40
41
- 42
43
44 9. Ayhan E, Aycicek F, Uyarel H, et al. Patients with anemia on admission
45
46 who have undergone primary angioplasty for ST elevation myocardial
47
48 infarction: in-hospital and long-term clinical outcomes. *Coron Artery Dis*
49
50 2011;22(6):375-9.
51
52
53
54
55
56
57
58
59
60

- 1
2
3 10. Kiviniemi T, Karjalainen P, Rubboli A, et al. Thrombocytopenia in patients
4
5 with atrial fibrillation on oral anticoagulation undergoing percutaneous
6
7 coronary intervention. *Am J Cardiol* 2013 Aug 15;112(4):493-8.
8
9
- 10
11 11. Schlitt A, Rubboli A, Lip GY, et al; for the AFCAS (Management of
12
13 patients with Atrial Fibrillation undergoing Coronary Artery Stenting Study
14
15 Group). The management of patients with atrial fibrillation undergoing
16
17 percutaneous coronary intervention with stent implantation: In-hospital-data
18
19 from the atrial fibrillation undergoing coronary artery stenting study.
20
21 *Catheter Cardiovasc Interv* 2013;82(7):E864-70
22
23
- 24
25 12. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for
26
27 cardiovascular clinical trials: a consensus report from the bleeding academic
28
29 research consortium, *Circulation* 2011;123:2736-2747.
30
31
32
- 33
34 13. Nutritional anaemias. Report of a WHO scientific group. *World Health*
35
36 *Organ Tech* 1968;405:5–32.
37
38
- 39
40 14. Pilgrim T, Vetterli F, Kalesan B, et al. The impact of anemia on long-term
41
42 clinical outcome in patients undergoing revascularization with the
43
44 unrestricted use of drug-eluting stents. *Circ Cardiovasc Interv.*
45
46 2012;5(2):202-10.
47
48
- 49
50 15. Lee PC, Kini AS, Ahsan C, et al. Anemia is an independent predictor of
51
52 mortality after percutaneous coronary intervention. *J Am Coll Cardiol*
53
54 2004;44(3):541-6.
55
56
57
58
59
60

- 1
2
3 16.Kim TH, Koh YS, Chang K, et al; CathOlic university of Korea –
4
5 percutAneous Coronary inTervention registry investigators. Improved
6
7 anemia is associated with favorable long-term clinical outcomes in patients
8
9 undergoing PCI. *Coron Artery Dis* 2012;23(6):391-9.
10
11
12
13 17.Kitai Y, Ozasa N, Morimoto T, et al; on behalf of the CREDO-Kyoto
14
15 registry investigators. Prognostic implications of anemia with or without
16
17 chronic kidney disease in patients undergoing elective percutaneous
18
19 coronary intervention. *Int J Cardiol* 2013;168(6):5221-8.
20
21
22
23 18.Hosseini SK, Ansari MJ, Lotfi Tokaldany M, et al. Association between
24
25 preprocedural hemoglobin level and 1-year outcome of elective
26
27 percutaneous coronary intervention. *J Cardiovasc Med.* 2013 Feb 15. [Epub
28
29 ahead of print]
30
31
32
33 19.Manzano-Fernández S, Pastor FJ, Marín F, et al. Increased major bleeding
34
35 complications related to triple antithrombotic therapy usage in patients with
36
37 atrial fibrillation undergoing percutaneous coronary artery stenting. *Chest*
38
39 2008;134(3):559-67.
40
41
42
43 20.Toma C, Zahr F, Moguilanski D, et al. Impact of anemia on platelet
44
45 response to clopidogrel in patients undergoing percutaneous coronary
46
47 stenting. *Am J Cardiol* 2012;109(8):1148-53.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 21.Foley RN, Parfrey PS, Hamett JD, et al. The impact of anemia on
4
5 cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J
6
7 Kidney Dis 1996;28:53– 61.
8
9

10
11 22.Maluenda G, Lemesle G, Ben-Dor I, et al. Value of blood transfusion in
12
13 patients with a blood hematocrit of 24% to 30% after percutaneous coronary
14
15 intervention. Am J Cardiol 2009;104:1069 –1073.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FIGURE LEGENDS

Figure 1 Kaplan-Meier survival curves for the occurrence of adverse events in anemic (dotted lines) versus non-anemic (solid line) patients at 2-month follow-up: all-cause mortality (a), MACCE free survival (b) and bleeding event free survival (c)

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Patients at risk		0	3	6	9	12
Non-anemic	603	581	562	558	553	
Anemic	258	235	225	219	210	

Figure 1a

view only




Patients at risk		0	3	6	9	12
Non-anemic	603	552	521	507	486	
Anemic	258	215	202	195	181	

Figure 1b

view only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Patients at risk					
Non-anemic	603	507	485	476	463
Anemic	258	197	187	180	169

Figure 1c

view only

Table 1. Bleeding Academic Research Consortium Definition for Bleeding.

Type 2	any overt, actionable sign of hemorrhage (eg, more bleeding than would be expected for a clinical circumstance, including bleeding found by imaging alone) that does not fit the criteria for type 3, 4, or 5 but does meet at least one of the following criteria: (1) requiring nonsurgical, medical intervention by a healthcare professional, (2) leading to hospitalization or increased level of care, or (3) prompting evaluation
Type 3a	Overt bleeding plus hemoglobin drop of 3 to 5 g/dL* (provided hemoglobin drop is related to bleed) Any transfusion with overt bleeding
Type 3b	Overt bleeding plus hemoglobin drop >5 g/dL* (provided hemoglobin drop is related to bleed) Cardiac tamponade Bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemorrhoid) Bleeding requiring intravenous vasoactive agents
Type 3c	Intracranial hemorrhage (does not include microbleeds or hemorrhagic transformation, does include intraspinal) Subcategories confirmed by autopsy or imaging or lumbar puncture Intraocular bleed compromising vision
Type 5	fatal bleeding

Type 1 and type 4 (coronary bypass related) bleeding events were not included in the analysis.

Online Table 2 Bleeding events at 12-month follow-up in the two study subgroups

Endpoints	Anemia (N=258)	Non-anemic (N=603)	<i>p</i> value
BARC 2	22 (8.5)	48 (8.0)	0.786
BARC 3a bleeding	18 (7.0)	20 (3.3)	0.028
BARC 3b bleeding	10 (3.9)	22 (3.6)	0.846
BARC 3c bleeding	0 (0)	9 (1.5)	0.064
BARC 5 bleeding	4 (1.6)	5 (0.8)	0.464
Total adverse events	111 (43.0)	190 (31.5)	0.001

Variables are presented as frequency (percentage).

BARC indicates Bleeding Academic Research Consortium.

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract ok (b) Provide in the abstract an informative and balanced summary of what was done and what was found ok
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported ok
Objectives	3	State specific objectives, including any prespecified hypotheses ok
Methods		
Study design	4	Present key elements of study design early in the paper ok
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection ok
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up ok (b) For matched studies, give matching criteria and number of exposed and unexposed
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable ok
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why ok
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding ok (b) Describe any methods used to examine subgroups and interactions ok (c) Explain how missing data were addressed ok (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed ok (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders ok (b) Indicate number of participants with missing data for each variable of interest ok (c) Summarise follow-up time (eg, average and total amount) ok
Outcome data	15*	Report numbers of outcome events or summary measures over time ok
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included ok

		(b) Report category boundaries when continuous variables were categorized ok
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses ok
Discussion		
Key results	18	Summarise key results with reference to study objectives ok
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias ok
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence ok
Generalisability	21	Discuss the generalisability (external validity) of the study results ok
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based ok

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

BMJ Open

Impact of anemia on clinical outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention: insights from the AFCAS registry

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-004700.R2
Article Type:	Research
Date Submitted by the Author:	21-Apr-2014
Complete List of Authors:	Puurunen, Marja; Finnish Red Cross Blood Service, Laboratory of Hemostasis Kiviniemi, Tuomas; Turku University Hospital, Heart Center Nammass, Wail; Turku University Hospital, Heart Center Schlitt, Axel; Martin Luther University Halle-Wittenberg, Medical Faculty Rubboli, Andrea; Ospedale Maggiore, Division of Cardiology Nyman, Kai; Central Finland Central Hospital, Department of Cardiology Karjalainen, Pasi; Satakunta Central Hospital, Heart Center Kirchhof, Paulus; University of Birmingham, Centre for Cardiovascular Sciences Lip, Gregory; University Department of Medicine, Airaksinen, Juhani; Turku University Hospital, Heart Center
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Haematology (incl blood transfusion)
Keywords:	HAEMATOLOGY, CARDIOLOGY, Coronary intervention < CARDIOLOGY, Anaemia < HAEMATOLOGY, Anticoagulation < HAEMATOLOGY

SCHOLARONE™
Manuscripts

1
2
3
4 **Impact of anemia on clinical outcome in patients with atrial fibrillation**
5
6 **undergoing percutaneous coronary intervention: insights from the AFCAS**
7
8 **registry**
9
10

11
12
13
14 **Puurunen Marja***, **Kiviniemi Tuomas†**, **Nammas Wail†**, **Schlitt Axel ‡**, **Rubboli**

15 **Andrea§**, **Nyman Kai#**, **Karjalainen Pasi¶**, **Kirchhof Paulus††,****, **Lip Gregory YH††**,

16
17
18
19 **Airaksinen KE Juhani†**
20

21 * Hemostasis laboratory, Finnish Red Cross Blood Service, Helsinki, Finland

22 †Heart Center, Turku University Hospital and University of Turku, Turku, Finland;

23 ‡Medical Faculty, Martin Luther University Halle-Wittenberg, Halle-Wittenberg, Germany;

24 §Division of Cardiology, Laboratory of Interventional Cardiology, Ospedale Maggiore,
25 Bologna, Italy;

26 #Department of Cardiology, Central Finland Central Hospital, Jyväskylä, Finland;

27 ¶Heart Center, Satakunta Central Hospital, Pori, Finland;

28 ** Department of Cardiovascular Medicine, Hospital of the University of Münster, Münster,
29 Germany
30

31 ††University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham,
32 United Kingdom
33

34
35
36
37
38
39
40
41
42
43
44
45
46
47 **Address for correspondence:** Dr. K. E. Juhani Airaksinen, Heart Center, Turku University
48 Hospital, Kiinamylynkatu 4-8, FIN-20520 Turku, Finland.

49
50
51
52 Email: juhani.airaksinen@tyks.fi
53

54 **Word count** (excluding title page, abstract, tables, figures and references) 2751
55
56
57
58
59
60

ABSTRACT

Objectives: Anemia has an adverse impact on the outcome in the general patient population undergoing percutaneous coronary intervention (PCI). The aim of this study was to analyze the impact of anemia on the 12-month clinical outcome of patients with atrial fibrillation (AF) undergoing PCI and therefore requiring intense antithrombotic treatment. We hypothesized that anemia might be associated with a worse outcome and more bleeding in these anticoagulated patients.

Setting: Data was collected from 17 secondary care centers in Europe.

Participants: Consecutive patients with AF undergoing PCI were enrolled in the prospective, multicenter AFCAS (Atrial Fibrillation undergoing Coronary Artery Stenting) registry. Altogether 929 patients participated in the study. Preprocedural haemoglobin concentration was available for 861 (92.7%) (30% female). Only exclusion criteria were inability or unwillingness to give informed consent. Anemia was defined as a haemoglobin concentration of <12 g/dl for women, and <13 g/dl for men.

Outcome measures: The primary endpoint was occurrence of major adverse cardiac and cerebrovascular events (MACCE) or bleeding events.

Results: 258/861 (30%) patients had anemia. Anemic patients were older, had more often diabetes, higher CHA₂DS₂-VASc score, prior history of heart

1
2
3 failure, chronic renal impairment, and acute coronary syndrome. Anemic
4
5 patients had more MACCE than non-anemic (29.1% versus 19.4%,
6
7 respectively, $p=0.002$), and minor bleeding events (7.0% versus 3.3%,
8
9 respectively, $p=0.028$), with a trend toward more total bleeding events (25.2%
10
11 versus 21.7%, respectively, $p=0.059$). No difference was observed in
12
13 antithrombotic regimens at discharge. In multivariate analysis anemia was an
14
15 independent predictor of all-cause mortality at 12-months follow-up (HR 1.62,
16
17 95% CI 1.05 – 2.51, $p=0.029$).
18
19
20
21
22
23

24 **Conclusions:** Anemia was a frequent finding in patients with AF referred for
25
26 PCI. Anemic patients had a higher all-cause mortality, more thrombotic events,
27
28 and minor bleeding events. Anemia seems to identify patients at risk for
29
30 cardiovascular events and death.
31
32
33

34
35 **Trial registration:** ClinicalTrials.gov number NCT00596570
36
37
38
39

40 **Keywords:** atrial fibrillation, percutaneous coronary intervention, anemia
41
42
43
44
45

46 **Strengths and limitations of the study:**

- 47
48 - The strength of the study is the enrolment of consecutive patients with
49
50 the only exclusion criteria being unwillingness/inability to participate in
51
52 the study. In this sense the study population represents well real-world
53
54 patients with AF referred for PCI.
55
56
57
58
59
60

- The study adds to our knowledge on the prevalence and impact of anemia in AF patients undergoing PCI and thus requiring combination antithrombotic medication. It shows that anemia is a frequent finding and that even mild anemia has an adverse impact on outcome.
- The current study has the inherent limitations of the observational study design, including individual risk-based decision making in treatment choices, which may introduce selection bias. Another possible confounder is the heterogeneity of the AF population among the participating centers and some differences in the periprocedural routines.
- The aetiology of anemia could not be systematically investigated and is therefore out of the scope of this study.

INTRODUCTION

It is estimated that around 5% of patients undergoing percutaneous coronary intervention (PCI) need long-term oral anticoagulation (OAC) due to atrial fibrillation (AF).[1,2] Yet, the current recommendations on the management of antithrombotic treatment in patients with AF undergoing PCI and stenting are mainly derived from small studies, amounting to a weak level of evidence.[3,4] Moreover, the real-world management of patients on OAC undergoing PCI is variable, and only partially adherent to the current recommendations.[5]

Defined according to the World Health Organization (WHO), anemia has been reported to affect nearly 25% of patients undergoing PCI and stenting. Anemic patients undergoing PCI are generally older with more comorbidities, and have higher rates of in-hospital mortality and major adverse cardiac and cerebrovascular events (MACCE), as well as 1-year mortality.[6,7] Furthermore, low admission haemoglobin level was found to be an independent predictor of in-hospital and long-term mortality, and was associated with higher rates of in-hospital minor and major bleeding events in patients undergoing primary PCI for ST-segment elevation myocardial infarction (MI).[8,9]

However, little is known about the effect of anemia on the outcome of patients with AF undergoing PCI and thus requiring intensive antithrombotic treatment. Anemia is possibly a marker of high bleeding risk, which could be aggravated by the underlying cause. Therefore, we analyzed data from the

1
2
3 prospective AFCAS (Atrial Fibrillation undergoing Coronary Artery Stenting)
4
5 registry to explore the impact of anemia on the 12-month clinical outcome of
6
7 patients with AF undergoing PCI.[10]
8
9

10 11 12 13 **METHODS**

14 15 **Patients**

16
17 The AFCAS registry (ClinicalTrials.gov number NCT00596570)
18
19 is a prospective, multicenter registry that enrolled patients with AF referred for
20
21 PCI in 5 European countries. The study design has been described in detail
22
23 previously.[11] Patients were enrolled if they had: 1) history of AF
24
25 (paroxysmal, persistent, or permanent), or 2) on-going AF during the index
26
27 PCI. Out of the 929 participants 861 (92.7%) had a preprocedural haemoglobin
28
29 count available and were included in this analysis.
30
31
32
33
34
35
36
37
38
39

40
41 Coronary angiography and PCI were performed via either radial or femoral
42
43 access, and hemostasis was achieved according to local practice. Coronary
44
45 lesions were treated according to contemporary interventional techniques. Low-
46
47 molecular-weight heparin (enoxaparin sodium, dalteparin), unfractionated
48
49 heparin, bivalirudin, and glycoprotein IIb/IIIa inhibitors were administered at
50
51 the operator's discretion. The post-discharge medication was completely at the
52
53 discretion of the treating physician.
54
55
56
57
58
59
60

1
2
3
4
5
6 The primary endpoints of the current study were 1) occurrence of MACCE
7
8 defined as a composite of all-cause mortality, any non-fatal MI, any
9
10 revascularization, definite/probable stent thrombosis, transient ischemic attack
11
12 (TIA) or stroke, and peripheral arterial embolism; 2) bleeding events; and 3)
13
14 total adverse events (a composite of MACCE plus bleeding events). Bleeding
15
16 events were defined according to the Bleeding Academic Research Consortium
17
18 (BARC) criteria as minor (BARC 2), and major (BARC 3a, 3b, 3c and 5)
19
20 bleeding events; however, CABG-related bleeding was excluded.[12] (Web
21
22 Table 1)
23
24
25
26
27
28
29
30
31

32 Anemia was defined as a haemoglobin concentration of <12 g/dl for women,
33
34 and <13 g/dl for men, according to the definition of the WHO.[13] Chronic
35
36 renal impairment was defined by an estimated glomerular filtration rate below
37
38 60 ml/min.
39
40
41
42
43
44

45 **Ethical aspects**

46
47
48 The study was initiated by the investigators and conducted according to the
49
50 ethical guidelines of the 1964 Declaration of Helsinki, as revised in 2002.
51
52
53 Informed written consent was obtained from every patient after full explanation
54
55
56
57
58
59
60

of the study protocol. The study protocol was approved by the ethics committees of the participating centers.

Statistical analysis

For analysis patients with available preprocedural measurement of haemoglobin concentration were divided into two subgroups: anemic patients, and control patients without anemia. Continuous variables were reported as the mean \pm standard deviation if normally distributed, and as median [inter-quartile range (IQR)] if they were skewed. Data were tested for normal distribution using the Kolmogorov-Smirnov and Shapiro-Wilk tests. Categorical variables were described with absolute and relative (percentage) frequencies. Comparisons between the two study subgroups were performed using the unpaired *t*-test or Mann-Whitney test for continuous variables, and Pearson χ^2 or Fisher's exact test for categorical variables, as appropriate. Cox regression hazard model was used to identify the independent predictors of MACCE, and all-cause mortality at 12-month follow-up. Baseline variables correlating at $p < 0.10$ level with the dependent variable in univariate analyses were entered in the Cox regression model as covariates. Cox regression hazard model was used to identify the independent predictors of MACCE, and all-cause mortality at 12-month follow-up in the subgroup of anemic patients. Finally we constructed Kaplan-Meier survival curves to display the time-to-event relationship for the occurrence of

1
2
3 all-cause mortality, MACCE, and all bleeding events. Statistical analysis was
4
5 performed using SPSS statistical software (SPSS v. 16.0.1, SPSS Inc., Chicago,
6
7 Ill., USA).
8
9

10 11 12 13 **RESULTS**

14 15 **Baseline characteristics**

16
17
18 Out of 929 patients enrolled in the AFCAS registry and followed up for 12
19
20 months, 861 (92.7%) had available preprocedural measurement of haemoglobin
21
22 concentration, of whom 258 (30%) had anemia and 603 (70%) had normal
23
24 haemoglobin concentration. Anemic patients were older, more likely to have
25
26 diabetes mellitus, hypertension, history of heart failure and chronic renal
27
28 impairment, HAS-BLED score ≥ 3 , higher CHA₂DS₂VASC score, and more
29
30 likely presented with acute coronary syndrome (ACS) as opposed to chronic
31
32 stable angina, compared with those without anemia ($p < 0.05$ for all), as shown
33
34 in Table 1. Furthermore, anemic patients had more vessels treated during the
35
36 index procedure, and a greater total stent length, compared with those without
37
38 anemia ($p < 0.05$ for both) (Table 2). At discharge, no significant differences
39
40 were seen in the prescription of antithrombotic medications in the two study
41
42 groups ($p = 0.15$) (Table 3). The duration of clopidogrel treatment did not differ
43
44 in anemic versus non-anemic patients on triple therapy (median [IQR]: 3 [11]
45
46 versus 3 [5] months, $p = 0.61$), on dual antiplatelet therapy (median [IQR]: 12
47
48
49
50
51
52
53
54
55
56
57
58
59
60

[11] versus 12 [11] months, $p=0.72$), or on vitamin K antagonist + clopidogrel (median [IQR]: 12 [11] versus 3 [11] months, $p=0.65$). Proton pump inhibitors were more frequently prescribed to patients with anemia versus those without (47.7 versus 31.3%, respectively, $p < 0.001$).

Table 1 Baseline clinical characteristics of the two study subgroups

Variable	Anemia (N=258)	Non-anemic (N=603)	<i>p</i> value
Age (yrs)	76 [9]	73 [11]	<0.001
Female gender	89 (34.5)	170 (28.2)	0.074
Diabetes mellitus	119 (46.1)	191 (31.7)	<0.001
Hypercholesterolemia	162 (62.8)	407 (67.5)	0.183
Current or ex-smoking	26 (10.1)	62 (10.3)	1.00
Hypertension	221 (85.7)	503 (83.4)	0.48
Paroxysmal atrial fibrillation	103 (39.9)	229 (38.0)	0.594
Persistent atrial fibrillation	22 (8.5)	78 (12.9)	0.081
Permanent atrial fibrillation	129 (50)	294 (48.8)	0.766

1				
2				
3				
4	CHA ₂ DS ₂ -VASc score >4	148 (57.4)	235 (39.0)	<0.001
5				
6	HAS BLED score ≥3	215 (83.3)	441 (73.1)	0.001
7				
8				
9	History of peptic ulcer	17 (6.6)	27 (4.5)	0.236
10				
11				
12	History of cerebral hemorrhage	4 (1.6)	6 (1.0)	0.497
13				
14				
15	History of GI hemorrhage	9 (3.5)	12 (2.0)	0.144
16				
17				
18	History of heart failure	69 (26.7)	113 (18.7)	0.011
19				
20				
21	eGFR below 60 ml/min	119 (52.2)	175 (31.9)	<0.001
22				
23				
24	Prior transient ischemic attacks	12 (4.7)	30 (5.0)	1.00
25				
26				
27				
28	Prior stroke	36 (14.0)	67 (11.1)	0.252
29				
30				
31	Prior MI	76 (29.5)	146 (24.2)	0.126
32				
33				
34	Prior PCI	47 (18.2)	100 (16.6)	0.555
35				
36				
37	Prior coronary bypass surgery	47 (18.2)	78 (12.9)	0.057
38				
39				
40	Proton pump inhibitors	123 (47.7)	189 (31.3)	<0.001
41				
42				
43	Stable angina pectoris	81 (31.4)	289 (48.0)	<0.001
44				
45				
46	ACS	177 (68.6)	313 (52.0)	<0.001
47				
48				
49	Unstable angina pectoris	53 (20.5)	107 (17.7)	0.34
50				
51				
52	Non-ST-elevation MI	83 (32.2)	132 (21.9)	0.002
53				
54				
55	ST-elevation MI	41 (15.9)	74 (12.3)	0.156
56				
57				
58				
59				
60				

Continuous variables are presented as median [interquartile range], whereas categorical variables are presented as frequency (percentage).

ACS indicates acute coronary syndrome; eGFR, estimated glomerular filtration rate; GI, gastrointestinal, IQR, inter-quartile range; MI, myocardial infarction; PCI, percutaneous coronary intervention.

Table 2 Procedural data of the two study subgroups

Variable	Anemia (N=258)	Non-anemic (N=603)	<i>p</i> value
Femoral access	196 (76.0)	435 (72.1)	0.275
Number of treated vessels	1.22 ± 0.45	1.15 ± 0.41	0.04
DES	67 (27.0)	138 (23.6)	0.293
Peri-procedural INR	1.9 [1]	1.88 [1]	0.509
Stent diameter (mm)	3 [1]	3 [1]	0.965
Total stent length (mm)	20 [18]	19 [14]	0.014
Procedural success	252 (97.7)	582 (96.5)	0.085
Hemostasis			
Manual compression	112 (43.4)	249 (41.3)	0.765
Compression device ^a	49 (19.0)	155 (25.7)	0.083
Access-site closure device ^b	82 (31.8)	165 (27.4)	0.154

Continuous variables are presented as mean \pm SD or median [interquartile range], whereas categorical variables are presented as frequency (percentage).

^aFemoStop[®], pneumatic compression device (Radi medical system, Sweden).

^bAngioseal[®], closure device (St. Jude medical, USA).

DES, drug-eluting stents; INR, international normalized ratio; IQR, inter-quartile range.

Table 3 Prescription of antithrombotic medications at discharge in the two study subgroups

Variable	Anemia (N=258)	Non-anemic (N=603)	<i>p</i> value
Triple therapy	181 (70.2)	442 (73.3)	0.15
DAPT	58 (22.5)	100 (16.6)	
VKA plus clopidogrel	15 (5.8)	51 (8.5)	
VKA plus aspirin	4 (1.6)	10 (1.7)	

Variables are presented as frequency (percentage).

VKA indicates vitamin K antagonist; DAPT, dual antiplatelet therapy.

Clinical outcome

Clinical outcomes at 12-month follow-up are presented in table 4 and figure 1.

The primary endpoint of MACCE was significantly more frequent in anemic patients than those without anemia (29.1 versus 19.4%, respectively, $p=0.002$).

This difference was driven by higher rates of all-cause mortality, non-fatal MI, and definite/probable ST ($p<0.05$ for all). Anemic patients had more BARC 3a bleeding events (7.0 versus 3.3%, respectively, $p=0.028$). No difference was

1
2
3 seen in BARC 5 bleedings. There was a trend toward more total bleeding
4
5 events (25.2% in anemic versus 21.7% in controls, $p=0.059$). (For detailed
6
7 information on bleeding events see Web Table 2.) Total adverse events
8
9 occurred more frequently in anemic versus non-anemic patients (43.0 versus
10
11 31.5%, respectively, $p=0.001$).
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 4 Clinical outcome at 12-month follow-up in the two study subgroups

Endpoints	Anemia (N=258)	Non-anemic (N=603)	p value
MACCE	75 (29.1)	117 (19.4)	0.002
All-cause mortality	48 (18.6)	50 (8.3)	<0.001
Stroke/TIA	6 (2.3)	17 (2.8)	0.819
Peripheral arterial embolism	2 (0.8)	5 (0.8)	1.00
Non-fatal myocardial infarction	24 (9.3)	27 (4.5)	0.011
Any revascularization	19 (7.4)	51 (8.5)	0.683
Definite/probable stent thrombosis	10 (3.9)	4 (0.7)	0.002
Total bleeding events	65 (25.2)	131 (21.7)	0.059
Minor bleeding (BARC 2)	22 (8.5)	48 (8.0)	0.786
Major bleeding (BARC 3a, 3b, 3c, 5)	33 (12.8)	56 (9.3)	0.142
Access site complications	25 (9.7)	49 (8.1)	0.51
Pseudoaneurysm	7 (2.7)	18 (3.0)	1.0
Red blood cell transfusion	10 (3.9)	5 (0.9)	0.002
Need for corrective surgery	5 (1.9)	8 (1.3)	0.25
Prolonged hospitalization	15 (5.8)	23 (3.8)	0.21
Total adverse events	111 (43.0)	190 (31.5)	0.001

Variables are presented as frequency (percentage).

MACCE indicates major adverse cardiac and cerebrovascular events; TIA, transient ischemic attacks; BARC, Bleeding Academic Research Consortium.

1
2
3 The incidence of definite/probable stent thrombosis was significantly higher in
4 anemic versus non-anemic patients (3.9 versus 0.7%, respectively, $p=0.002$).
5
6 Patients who developed stent thrombosis more often presented with ACS than
7
8 those who did not (80.0 versus 56.6%, respectively, $p=0.07$); however, the use
9
10 of triple therapy did not differ statistically between groups (60.0 versus 73.3%,
11
12 respectively, $p=0.25$). Overall, nearly half (46.7%) of ST events occurred early
13
14 (<30 days). Acute (<24h after index PCI); early (<30 days) and late ST (>30
15
16 and < 365 days) were detected in 1 (0.4%) and 1 (0.2%) ($p=0.51$); 4 (1.6%) vs.
17
18 2 (0.3%) ($p=0.07$); and 6 (2.3%) vs. 2 (0.3%) ($p=0.01$) in patients with anemia
19
20 vs. those without anemia, respectively.
21
22
23
24
25
26
27
28
29
30
31

32 In univariate analysis age above 75, diabetes, congestive heart failure, anemia,
33
34 chronic renal impairment, ACS at presentation, and total stent length were
35
36 strongly correlated with both MACCE and all-cause mortality at 12-month
37
38 follow-up. In the Cox regression model including all the above variables,
39
40 independent predictors of all-cause mortality were anemia (HR 1.62, 95% CI
41
42 1.05 – 2.51, $p=0.029$), ACS at presentation (HR 2.26, 95% CI 1.37 – 3.75,
43
44 $p=0.001$), chronic renal impairment (HR 2.35, 95% CI 1.52 – 3.65, $p<0.001$),
45
46 and diabetes (HR 1.76, 95% CI 1.15 – 2.70, $p=0.009$). In contrast, anemia as a
47
48 categorical variable was not an independent predictor of MACCE at 12-months
49
50 follow-up unlike age above 75 years (HR 1.7, 95%-CI 1.2-2.4, $p=0.004$),
51
52
53
54
55
56
57
58
59
60

1
2
3 diabetes (HR 1.7, 95%-CI 1.2-2.3, p=0.002), ACS at presentation (HR 1.7,
4
5 95%-CI 1.2-2.3, p=0.003), and congestive heart failure (HR 1.5, 95%-CI 1.0-
6
7 2.1, p=0.03).

8
9
10 We performed the multivariate model also using haemoglobin as a continuous
11
12 variable. Independent predictors of all-cause mortality were pre-procedural
13
14 haemoglobin (HR 0.82, 95% CI 0.72 – 0.93, p=0.002), ACS at presentation
15
16 (HR 2.07, 95% CI 1.25 – 3.45, p=0.005), chronic renal impairment (HR 2.06,
17
18 95% CI 1.31 – 3.24, p=0.002), and diabetes (HR 1.75, 95% CI 1.14 – 2.70,
19
20 p=0.01) in a Cox regression model including age over 75 years, total stent
21
22 length and number of treated vessels as covariates. On the contrary to what
23
24 was found when assessing anemia as a categorical variable, haemoglobin as a
25
26 continuous variable predicted also MACCE. Independent predictors of
27
28 MACCE were pre-procedural haemoglobin (HR 0.89, 95% CI 0.81 – 0.98,
29
30 p=0.016), ACS at presentation (HR 1.55, 95% CI 1.10 – 2.18, p=0.012),
31
32 congestive heart failure (HR 1.45, 95% CI 1.03 – 2.04, p=0.035), age over 75
33
34 years (HR 1.77, 95%CI 1.27 – 2.45, p=0.001) and diabetes (HR 1.55, 95% CI
35
36 1.13 – 2.13, p=0.007) in a Cox regression model including also total stent
37
38 length, chronic renal impairment and number of treated vessels as covariates.
39
40
41
42
43
44
45
46
47
48
49

50 When the anemic patients were analysed separately in the Cox
51
52 regression model, age over 75 years and ACS at presentation were identified as
53
54 independent predictors of MACCE at 12-months; and chronic renal
55
56
57
58
59
60

1
2
3 impairment, age over 75 years and ACS at presentation as independent
4
5 predictors of all-cause mortality
6
7

8
9 Among 861 patients with available preprocedural measurement of
10
11 haemoglobin concentration, 26 (2.8%) had severe anemia (defined as
12
13 haemoglobin below 10 g/dl). In this subgroup, MACCE occurred in 12 (46.2%)
14
15 patients, 10 (38.5%) patients died, and 8 (30.8%) experienced a BARC 2-5
16
17 bleeding episode. At discharge, triple therapy was prescribed in 18 (69.2%)
18
19 patients, dual anti-platelet therapy in 8 (30.8%), and no patient was prescribed
20
21 vitamin K antagonists plus a single anti-platelet drug. Proton pump inhibitors
22
23 were prescribed at discharge in 18 (69.2%) patients, and one (3.8%) patient had
24
25 a history of gastrointestinal bleeding.
26
27
28
29
30
31
32
33
34

35 **DISCUSSION**

36
37 Our study is the first report on the impact of anemia on the long-term clinical
38
39 outcome of patients with AF undergoing PCI. The AFCAS registry represent a
40
41 real-life cohort of high-risk AF-patients requiring PCI. The results of the
42
43 current study showing that 30% of the patients were anemic confirm the
44
45 previous reports that anemia is a frequent finding in real-world patients with
46
47 AF referred for PCI.[6-9,14] Anemic patients in the AFCAS registry were older
48
49 with more comorbidities, and presented more often with ACS, compared with
50
51 non-anemic patients, as also reported in previous cohorts.[6,7,9,14].
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 Overall, the 12-month clinical outcome was worse in anemic patients. Anemia
7
8 remained an independent predictor of all-cause mortality in multivariate
9
10 analysis. The higher rate of all-cause mortality might be related to the higher-
11
12 risk profile in anemic patients, as well as the underlying disease causing
13
14 anemia. Furthermore, anemic patients had more frequent MACCE at 12
15
16 months, primarily driven by higher rates of all-cause mortality, and non-fatal
17
18 MI. However, anemia was not an independent predictor of MACCE. The higher
19
20 rate of non-fatal MI might be explained, at least in part, by the higher frequency
21
22 of ACS at presentation in anemic patients.
23
24
25
26
27
28
29
30
31

32 The estimated thromboembolic risk of anemic patients according to CHADS₂
33
34 score was higher. However, no excess in TIA or stroke was seen during the
35
36 follow-up and only a trend towards more bleeding was observed. This is
37
38 contradictory to previous studies which have reported a higher incidence of
39
40 cardiac and cerebrovascular thrombotic events at long-term follow-up in
41
42 anemic versus non-anemic patients in various patient cohorts referred for
43
44 PCI.[7,9,14-18] The relatively small number of complications in our patient
45
46 cohort might explain this difference.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The estimated bleeding risk according to the HAS-BLED score was higher in
4
5
6 anemic patients, but there was only a trend towards increased risk of major
7
8
9 bleeding. However, the results of the current study support the previous reports
10
11 on the increased bleeding risk associated with anemia in various patient groups
12
13 undergoing PCI.[8,9,19] Anemia may be a marker and consequence of an
14
15 underlying condition such as bleeding diathesis, occult gastrointestinal
16
17 bleeding, or malignancy that augments the bleeding risk. An interesting
18
19 observation is that neither the presence of anemia nor higher estimated bleeding
20
21 risk seemed to affect the clinician's choice of antithrombotic medications at
22
23 discharge. In view of our results, patients with anemia tolerated triple therapy
24
25 surprisingly well with only a trend towards increased bleeding.
26
27
28
29
30
31
32
33
34

35 We observed that the rate of definite or probable stent thrombosis was
36
37 significantly higher in anemic versus non-anemic patients ($p = 0.002$). ACS at
38
39 presentation may have contributed to the higher rate of stent thrombosis in
40
41 anemic patients, as patients with anemia more often presented with ACS versus
42
43 those without anemia. In addition, in individual cases the presence of anemia
44
45 may have influenced the choice of antithrombotic medication. Also, a bleeding
46
47 event could have lead to interruption of combination antithrombotic therapy
48
49 and thus to a higher risk of stent thrombosis. Consistent with our results,
50
51 Pilgrim and co-workers, observed a higher rate of definite stent thrombosis at
52
53
54
55
56
57
58
59
60

1
2
3 4-year follow-up in anemic patients who underwent PCI with unrestricted use
4
5 of drug-eluting stents, compared with non-anemic ones.[14] Interestingly, in a
6
7 recent study, anemia was the only independent predictor of high residual
8
9 platelet reactivity on clopidogrel in a series of patients undergoing PCI.[20]
10
11 These observations warrant further studies to clarify the underlying
12
13 mechanisms.
14
15
16
17
18
19
20

21
22 The effect of anemia on the clinical outcome of PCI appears early during
23
24 hospitalization. Kaplan-Meier event-free survival curves in the current study
25
26 revealed that most of the thrombotic as well as bleeding events occurred early
27
28 (within 30 days) following the index PCI (Figure 1). This finding is in line with
29
30 previous reports.[6,8,9,15] In patients with coronary artery disease, anemia
31
32 may aggravate myocardial ischemia, and unveil significant coronary
33
34 obstruction. Cardiac output increases in patients with anemia in order to
35
36 maintain adequate oxygen delivery to the tissues. This increases heart rate and
37
38 induces myocardial hypertrophy, which in turn, increases myocardial oxygen
39
40 demand, and further exaggerates the myocardial oxygen demand/supply
41
42 imbalance.[21] On the other hand, patients with severe anemia receive more
43
44 frequent blood transfusion, which was reported to have an adverse impact on
45
46 survival after PCI.[22] Unfortunately, information on blood transfusions was
47
48 not available in our registry except for the in-hospital phase. More importantly,
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 anemia is frequently associated with severe underlying chronic diseases which
4
5 may compromise long-term survival. Of note is a recent report suggesting that
6
7 in patients who underwent PCI with drug-eluting stents, those in whom anemia
8
9 improved at follow-up had less MACCE at a median follow-up of 25 months,
10
11 compared with those with sustained anemia suggesting that a transient cause is
12
13 less detrimental than a long-standing state causing anemia, e.g. malignancy.[16]
14
15
16
17
18
19
20

21 **Limitations of the study**

22
23
24 The current study has the inherent limitations of the observational study design,
25
26 including individual risk-based decision making in treatment choices, which
27
28 may introduce selection bias, even though we did not observe any difference
29
30 between the two study groups in the antithrombotic treatment prescribed at
31
32 discharge. Another possible confounder is the heterogeneity of the AF
33
34 population among the participating centers and some differences in the
35
36 periprocedural routines. Moreover, the aetiology of anemia was not
37
38 systematically investigated; yet, it is beyond the scope of the current study. The
39
40 strength of the study is the enrolment of consecutive patients with the only
41
42 exclusion criteria being unwillingness/inability to participate in the study. In
43
44 this sense the study population represents well real-world patients with AF
45
46 referred for PCI.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conclusion

Anemia was a frequent finding in patients with AF referred for PCI. Anemia seems to be an independent risk factor for all-cause mortality during 12-month follow-up. Anemia is also associated with more MACCE, and a trend toward a higher rate of bleeding.

ACKNOWLEDGMENTS

We thank our study coordinator Tuija Vasankari, RN, for her valuable input in data management.

COMPETING INTERESTS

The authors declare no competing interests.

FUNDING

This study was supported by grants from the Finnish Foundation for Cardiovascular Research, Helsinki, Finland.

Contributorship statement: Marja Puurunen and Tuomas Kiviniemi participated in data collection and analysis and writing the manuscript; Wail Nammas contributed to data analysis and writing of the manuscript; Axel Schlitt, Andrea Rubboli, Kai Nyman, Pasi Karjalainen and Paulus Kirchhof contributed to data collection and critical revision of the manuscript; Gregory Lip contributed to study design, data collection and critical revision of the manuscript; Juhani Airaksinen acted as the primary investigator of the AFCAS

1
2
3 study and contributed to study design, data collection, data analysis and writing
4
5 of the manuscript.
6
7

8
9
10 **Data sharing** The whole study data is available from the study coordinator Ms.
11
12 Tuija Vasankari email: tuija.vasankari@tyks.fi or Dr. Tuomas Kiviniemi email:
13
14 tuomas.kiviniemi@utu.fi in addition to corresponding author Prof. Juhani
15
16 Airaksinen email: juhani.airaksinen@tyks.fi.
17
18
19

20 21 22 23 24 **REFERENCES**

- 25
26
27 1. Rubboli A, Halperin JL, Airaksinen KE, et al. Antithrombotic therapy in
28
29 patients treated with oral anticoagulation undergoing coronary artery
30
31 stenting. An expert consensus document with focus on atrial fibrillation.
32
33 Ann Med 2008;40(6):428-36.
34
35
36
37 2. Rubboli A, Colletta M, Valencia J, et al for the WARfarin, Coronary
38
39 STENTing (WAR-STENT) Study Group. Periprocedural management and
40
41 in-hospital outcome of patients with indication for oral anticoagulation
42
43 undergoing coronary artery stenting. J Interv Cardiol 2009;22:390–397.
44
45
46
47 3. Lip GYH, Huber K, Andreotti F, et al. Antithrombotic management of atrial
48
49 fibrillation patients presenting with acute coronary syndrome and/or
50
51 undergoing coronary stenting: executive summary—a Consensus Document
52
53
54
55
56 of the European Society of Cardiology Working Group on Thrombosis,
57
58
59
60

1
2
3 endorsed by the European Heart Rhythm Association (EHRA) and the
4
5 European Association of Percutaneous Cardiovascular Interventions
6
7 (EAPCI). *Eur Heart J* 2010;31:1311-1318.
8
9

- 10
11 4. Faxon DP, Eikelboom JW, Berger PB, et al. Consensus Document:
12
13 Antithrombotic therapy in patients with atrial fibrillation undergoing
14
15 coronary stenting. A North-American perspective. *Thromb Haemost*
16
17 2011;106:522-84.
18
19
20
21 5. Rubboli A, Dewilde W, Huber K, et al. The management of patients on oral
22
23 anticoagulation undergoing coronary stent implantation: a survey among
24
25 interventional cardiologists from eight European countries. *J Interv Cardiol*
26
27 2012;25:163-9.
28
29
30
31 6. McKechnie RS, Smith D, Montoye C, et al; Blue Cross Blue Shield of
32
33 Michigan Cardiovascular Consortium (BMC2). Prognostic implication of
34
35 anemia on in-hospital outcomes after percutaneous coronary intervention.
36
37 *Circulation* 2004;110(3):271-7.
38
39
40
41
42 7. Nikolsky E, Mehran R, Aymong ED, et al. Impact of anemia on outcomes of
43
44 patients undergoing percutaneous coronary interventions. *Am J Cardiol*
45
46 2004;94(8):1023-7.
47
48
49
50 8. Dündar C, Oduncu V, Erkol A, et al. In-hospital prognostic value of
51
52 hemoglobin levels on admission in patients with acute ST segment elevation
53
54
55
56
57
58
59
60

- 1
2
3 myocardial infarction undergoing primary angioplasty. *Clin Res Cardiol*
4
5
6 2012;101(1):37-44.
7
8
9 9. Ayhan E, Aycicek F, Uyarel H, et al. Patients with anemia on admission
10
11 who have undergone primary angioplasty for ST elevation myocardial
12
13 infarction: in-hospital and long-term clinical outcomes. *Coron Artery Dis*
14
15 2011;22(6):375-9.
16
17
18
19 10. Kiviniemi T, Karjalainen P, Rubboli A, et al. Thrombocytopenia in patients
20
21 with atrial fibrillation on oral anticoagulation undergoing percutaneous
22
23 coronary intervention. *Am J Cardiol* 2013 Aug 15;112(4):493-8.
24
25
26
27 11. Schlitt A, Rubboli A, Lip GY, et al; for the AFCAS (Management of
28
29 patients with Atrial Fibrillation undergoing Coronary Artery Stenting Study
30
31 Group). The management of patients with atrial fibrillation undergoing
32
33 percutaneous coronary intervention with stent implantation: In-hospital-data
34
35 from the atrial fibrillation undergoing coronary artery stenting study.
36
37 *Catheter Cardiovasc Interv* 2013;82(7):E864-70
38
39
40
41
42
43 12. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for
44
45 cardiovascular clinical trials: a consensus report from the bleeding academic
46
47 research consortium, *Circulation* 2011;123:2736-2747.
48
49
50
51 13. Nutritional anaemias. Report of a WHO scientific group. *World Health*
52
53 *Organ Tech* 1968;405:5-32.
54
55
56
57
58
59
60

- 1
2
3 14. Pilgrim T, Vetterli F, Kalesan B, et al. The impact of anemia on long-term
4
5 clinical outcome in patients undergoing revascularization with the
6
7 unrestricted use of drug-eluting stents. *Circ Cardiovasc Interv.*
8
9 2012;5(2):202-10.
10
11
12
13 15. Lee PC, Kini AS, Ahsan C, et al. Anemia is an independent predictor of
14
15 mortality after percutaneous coronary intervention. *J Am Coll Cardiol*
16
17 2004;44(3):541-6.
18
19
20
21 16. Kim TH, Koh YS, Chang K, et al; CathOlic university of Korea –
22
23 percutaneous Coronary inTervention registry investigators. Improved
24
25 anemia is associated with favorable long-term clinical outcomes in patients
26
27 undergoing PCI. *Coron Artery Dis* 2012;23(6):391-9.
28
29
30
31
32 17. Kitai Y, Ozasa N, Morimoto T, et al; on behalf of the CREDO-Kyoto
33
34 registry investigators. Prognostic implications of anemia with or without
35
36 chronic kidney disease in patients undergoing elective percutaneous
37
38 coronary intervention. *Int J Cardiol* 2013;168(6):5221-8.
39
40
41
42
43 18. Hosseini SK, Ansari MJ, Lotfi Tokaldany M, et al. Association between
44
45 preprocedural hemoglobin level and 1-year outcome of elective
46
47 percutaneous coronary intervention. *J Cardiovasc Med.* 2013 Feb 15. [Epub
48
49 ahead of print]
50
51
52
53 19. Manzano-Fernández S, Pastor FJ, Marín F, et al. Increased major bleeding
54
55 complications related to triple antithrombotic therapy usage in patients with
56
57
58
59
60

atrial fibrillation undergoing percutaneous coronary artery stenting. *Chest* 2008;134(3):559-67.

20.Toma C, Zahr F, Moguilanski D, et al. Impact of anemia on platelet response to clopidogrel in patients undergoing percutaneous coronary stenting. *Am J Cardiol* 2012;109(8):1148-53.

21.Foley RN, Parfrey PS, Hamett JD, et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. *Am J Kidney Dis* 1996;28:53– 61.

22.Maluenda G, Lemesle G, Ben-Dor I, et al. Value of blood transfusion in patients with a blood hematocrit of 24% to 30% after percutaneous coronary intervention. *Am J Cardiol* 2009;104:1069 –1073.

FIGURE LEGENDS

Figure 1 Kaplan-Meier survival curves for the occurrence of adverse events in anemic (dotted lines) versus non-anemic (solid line) patients at 2-month follow-up: all-cause mortality (a), MACCE free survival (b) and bleeding event free survival (c)


For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




		Time after index PCI (months)				
Patients at risk		0	3	6	9	12
Non-anemic	603	581	562	558	553	
Anemic	258	235	225	219	210	

Figure 1a
119x90mm (300 x 300 DPI)

View only


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



		Patients at risk				
		0	3	6	9	12
Non-anemic	603	552	521	507	486	
Anemic	258	215	202	195	181	

Figure 1b
119x90mm (300 x 300 DPI)

View only



		Time after index PCI (months)				
Patients at risk		0	3	6	9	12
Non-anemic	603	507	485	476	463	
Anemic	258	197	187	180	169	

Figure 1c
119x90mm (300 x 300 DPI)

View only

Table 1. Bleeding Academic Research Consortium Definition for Bleeding.

Type 2	any overt, actionable sign of hemorrhage (eg, more bleeding than would be expected for a clinical circumstance, including bleeding found by imaging alone) that does not fit the criteria for type 3, 4, or 5 but does meet at least one of the following criteria: (1) requiring nonsurgical, medical intervention by a healthcare professional, (2) leading to hospitalization or increased level of care, or (3) prompting evaluation
Type 3a	Overt bleeding plus hemoglobin drop of 3 to 5 g/dL* (provided hemoglobin drop is related to bleed) Any transfusion with overt bleeding
Type 3b	Overt bleeding plus hemoglobin drop >5 g/dL* (provided hemoglobin drop is related to bleed) Cardiac tamponade Bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemorrhoid) Bleeding requiring intravenous vasoactive agents
Type 3c	Intracranial hemorrhage (does not include microbleeds or hemorrhagic transformation, does include intraspinal) Subcategories confirmed by autopsy or imaging or lumbar puncture Intraocular bleed compromising vision
Type 5	fatal bleeding

Type 1 and type 4 (coronary bypass related) bleeding events were not included in the analysis.

Online Table 2 Bleeding events at 12-month follow-up in the two study subgroups

Endpoints	Anemia (N=258)	Non-anemic (N=603)	<i>p</i> value
BARC 2	22 (8.5)	48 (8.0)	0.786
BARC 3a bleeding	18 (7.0)	20 (3.3)	0.028
BARC 3b bleeding	10 (3.9)	22 (3.6)	0.846
BARC 3c bleeding	0 (0)	9 (1.5)	0.064
BARC 5 bleeding	4 (1.6)	5 (0.8)	0.464
Total adverse events	111 (43.0)	190 (31.5)	0.001

Variables are presented as frequency (percentage).

BARC indicates Bleeding Academic Research Consortium.

1
2
3
4 **Impact of anemia on clinical outcome in patients with atrial fibrillation**
5
6 **undergoing percutaneous coronary intervention: insights from the AFCAS**
7
8 **registry**
9
10

11
12
13
14 **Puurunen Marja***, **Kiviniemi Tuomas†**, **Nammas Wail†**, **Schlitt Axel ‡**, **Rubboli**

15 **Andrea§**, **Nyman Kai#**, **Karjalainen Pasi¶**, **Kirchhof Paulus††,****, **Lip Gregory YH††**,

16
17
18
19 **Airaksinen KE Juhani†**
20

21 * Hemostasis laboratory, Finnish Red Cross Blood Service, Helsinki, Finland

22 †Heart Center, Turku University Hospital and University of Turku, Turku, Finland;

23 ‡Medical Faculty, Martin Luther University Halle-Wittenberg, Halle-Wittenberg, Germany;

24 §Division of Cardiology, Laboratory of Interventional Cardiology, Ospedale Maggiore,
25 Bologna, Italy;

26 #Department of Cardiology, Central Finland Central Hospital, Jyväskylä, Finland;

27 ¶Heart Center, Satakunta Central Hospital, Pori, Finland;

28 ** Department of Cardiovascular Medicine, Hospital of the University of Münster, Münster,
29 Germany
30

31 ††University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham,
32 United Kingdom
33

34
35
36
37
38
39
40
41
42
43
44
45
46
47 **Address for correspondence:** Dr. K. E. Juhani Airaksinen, Heart Center, Turku University
48 Hospital, Kiinamylynkatu 4-8, FIN-20520 Turku, Finland.

49
50
51
52 Email: juhani.airaksinen@tyks.fi
53

54 **Word count** (excluding title page, abstract, tables, figures and references) 27~~25~~51
55
56
57
58
59
60

1
2
3 **Contributorship statement:** Marja Puurunen and Tuomas Kiviniemi participated in data
4 collection and analysis and writing the manuscript; Wail Nammas contributed to data analysis
5 and writing of the manuscript; Axel Schlitt, Andrea Rubboli, Kai Nyman, Pasi Karjalainen
6 and Paulus Kirchhof contributed to data collection and critical revision of the manuscript;
7 Gregory Lip contributed to study design, data collection and critical revision of the
8 manuscript; Juhani Airaksinen acted as the primary investigator of the AFCAS study and
9 contributed to study design, data collection, data analysis and writing of the manuscript.
10
11
12
13
14
15
16
17
18
19
20

21 **Extra data** is available by emailing Prof. Juhani Airaksinen at juhani.airaksinen@tyks.fi.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives: Anemia has an adverse impact on the outcome in the general patient population undergoing percutaneous coronary intervention (PCI). The aim of this study was to analyze the impact of anemia on the 12-month clinical outcome of patients with atrial fibrillation (AF) undergoing PCI and therefore requiring intense antithrombotic treatment. We hypothesized that anemia might be associated with a worse outcome and more bleeding in these anticoagulated patients.

Setting: Data was collected from 17 secondary care centers in Europe.

Participants: Consecutive patients with AF undergoing PCI were enrolled in the prospective, multicenter AFCAS (Atrial Fibrillation undergoing Coronary Artery Stenting) registry. Altogether 929 patients participated in the study. Preprocedural haemoglobin concentration was available for 861 (92.7%) (30% female). Only exclusion criteria were inability or unwillingness to give informed consent. Anemia was defined as a haemoglobin concentration of <12 g/dl for women, and <13 g/dl for men.

Outcome measures: The primary endpoint was occurrence of major adverse cardiac and cerebrovascular events (MACCE) or bleeding events.

Results: 258/861 (30%) patients had anemia. Anemic patients were older, had more often diabetes, higher CHA₂DS₂-VASc score, prior history of heart

1
2
3 failure, chronic renal impairment, and acute coronary syndrome. Anemic
4
5 patients had more MACCE than non-anemic (29.1% versus 19.4%,
6
7 respectively, $p=0.002$), and minor bleeding events (7.0% versus 3.3%,
8
9 respectively, $p=0.028$), with a trend toward more total bleeding events (25.2%
10
11 versus 21.7%, respectively, $p=0.059$). No difference was observed in
12
13 antithrombotic regimens at discharge. In multivariate analysis anemia was an
14
15 independent predictor of all-cause mortality at 12-months follow-up (HR 1.62,
16
17 95% CI 1.05 – 2.51, $p=0.029$).
18
19
20
21
22
23

24 **Conclusions:** Anemia was a frequent finding in patients with AF referred for
25
26 PCI. Anemic patients had a higher all-cause mortality, more thrombotic events,
27
28 and minor bleeding events. Anemia seems to identify patients at risk for
29
30 cardiovascular events and death.
31
32
33

34
35 **Trial registration:** ClinicalTrials.gov number NCT00596570
36
37
38
39

40 **Keywords:** atrial fibrillation, percutaneous coronary intervention, anemia
41
42
43
44
45

46 **Strengths and limitations of the study:**
47

- 48 - The strength of the study is the enrolment of consecutive patients with
49
50 the only exclusion criteria being unwillingness/inability to participate in
51
52 the study. In this sense the study population represents well real-world
53
54 patients with AF referred for PCI.
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- The study adds to our knowledge on the prevalence and impact of anemia in AF patients undergoing PCI and thus requiring combination antithrombotic medication. It shows that anemia is a frequent finding and that even mild anemia has an adverse impact on outcome.
 - The current study has the inherent limitations of the observational study design, including individual risk-based decision making in treatment choices, which may introduce selection bias. Another possible confounder is the heterogeneity of the AF population among the participating centers and some differences in the periprocedural routines.
 - The aetiology of anemia could not be systematically investigated and is therefore out of the scope of this study.

INTRODUCTION

It is estimated that around 5% of patients undergoing percutaneous coronary intervention (PCI) need long-term oral anticoagulation (OAC) due to atrial fibrillation (AF).[1,2] Yet, the current recommendations on the management of antithrombotic treatment in patients with AF undergoing PCI and stenting are mainly derived from small studies, amounting to a weak level of evidence.[3,4] Moreover, the real-world management of patients on OAC undergoing PCI is variable, and only partially adherent to the current recommendations.[5]

Defined according to the World Health Organization (WHO), anemia has been reported to affect nearly 25% of patients undergoing PCI and stenting. Anemic patients undergoing PCI are generally older with more comorbidities, and have higher rates of in-hospital mortality and major adverse cardiac and cerebrovascular events (MACCE), as well as 1-year mortality.[6,7] Furthermore, low admission haemoglobin level was found to be an independent predictor of in-hospital and long-term mortality, and was associated with higher rates of in-hospital minor and major bleeding events in patients undergoing primary PCI for ST-segment elevation myocardial infarction (MI).[8,9]

However, little is known about the effect of anemia on the outcome of patients with AF undergoing PCI and thus requiring intensive antithrombotic treatment. Anemia is possibly a marker of high bleeding risk, which could be aggravated by the underlying cause. Therefore, we analyzed data from the

1
2
3 prospective AFCAS (Atrial Fibrillation undergoing Coronary Artery Stenting)
4
5
6 registry to explore the impact of anemia on the 12-month clinical outcome of
7
8 patients with AF undergoing PCI.[10]
9

10 11 12 13 **METHODS**

14 15 **Patients**

16
17 The AFCAS registry (ClinicalTrials.gov number NCT00596570)
18
19 is a prospective, multicenter registry that enrolled patients with AF referred for
20
21 PCI in 5 European countries. The study design has been described in detail
22
23 previously.[11] Patients were enrolled if they had: 1) history of AF
24
25 (paroxysmal, persistent, or permanent), or 2) on-going AF during the index
26
27 PCI. Out of the 929 participants 861 (92.7%) had a preprocedural haemoglobin
28
29 count available and were included in this analysis.
30
31
32
33
34
35
36
37
38
39

40
41 Coronary angiography and PCI were performed via either radial or femoral
42
43 access, and hemostasis was achieved according to local practice. Coronary
44
45 lesions were treated according to contemporary interventional techniques. Low-
46
47 molecular-weight heparin (enoxaparin sodium, dalteparin), unfractionated
48
49 heparin, bivalirudin, and glycoprotein IIb/IIIa inhibitors were administered at
50
51 the operator's discretion. The post-discharge medication was completely at the
52
53 discretion of the treating physician.
54
55
56
57
58
59
60

1
2
3
4
5
6 The primary endpoints of the current study were 1) occurrence of MACCE
7
8 defined as a composite of all-cause mortality, any non-fatal MI, any
9
10 revascularization, definite/probable stent thrombosis, transient ischemic attack
11
12 (TIA) or stroke, and peripheral arterial embolism; 2) bleeding events; and 3)
13
14 total adverse events (a composite of MACCE plus bleeding events). Bleeding
15
16 events were defined according to the Bleeding Academic Research Consortium
17
18 (BARC) criteria as minor (BARC 2), and major (BARC 3a, 3b, 3c and 5)
19
20 bleeding events; however, CABG-related bleeding was excluded.[12]
21
22

23
24
25
26
27 ([WebOnline](#) Table 1)
28
29
30
31

32 Anemia was defined as a haemoglobin concentration of <12 g/dl for women,
33
34 and <13 g/dl for men, according to the definition of the WHO.[13] Chronic
35
36 renal impairment was defined by an estimated glomerular filtration rate below
37
38 60 ml/min.
39
40
41
42
43
44

45 **Ethical aspects**

46
47
48 The study was initiated by the investigators and conducted according to the
49
50 ethical guidelines of the 1964 Declaration of Helsinki, as revised in 2002.
51
52
53 Informed written consent was obtained from every patient after full explanation
54
55
56
57
58
59
60

1
2
3 of the study protocol. The study protocol was approved by the ethics
4
5 committees of the participating centers.
6
7
8
9

10 11 **Statistical analysis**

12
13 For analysis patients with available preprocedural measurement of haemoglobin
14 concentration were divided into two subgroups: anemic patients, and control
15 patients without anemia. Continuous variables were reported as the mean \pm
16 standard deviation if normally distributed, and as median [inter-quartile range
17 (IQR)] if they were skewed. Data were tested for normal distribution using the
18 Kolmogorov-Smirnov and Shapiro-Wilk tests. Categorical variables were
19 described with absolute and relative (percentage) frequencies. Comparisons
20 between the two study subgroups were performed using the unpaired *t*-test or
21 Mann-Whitney test for continuous variables, and Pearson χ^2 or Fisher's exact
22 test for categorical variables, as appropriate. Cox regression hazard model was
23 used to identify the independent predictors of MACCE, and all-cause mortality
24 at 12-month follow-up. Baseline variables correlating at $p < 0.10$ level with the
25 dependent variable in univariate analyses were entered in the Cox regression
26 model as covariates. Cox regression hazard model was used to identify the
27 independent predictors of MACCE, and all-cause mortality at 12-month follow-
28 up in the subgroup of anemic patients. Finally we constructed Kaplan-Meier
29 survival curves to display the time-to-event relationship for the occurrence of
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 all-cause mortality, MACCE, and all bleeding events. Statistical analysis was
4
5 performed using SPSS statistical software (SPSS v. 16.0.1, SPSS Inc., Chicago,
6
7 Ill., USA).
8
9

10 11 12 13 **RESULTS**

14 **Baseline characteristics**

15
16
17
18 Out of 929 patients enrolled in the AFCAS registry and followed up for 12
19
20 months, 861 (92.7%) had available preprocedural measurement of haemoglobin
21
22 concentration, of whom 258 (30%) had anemia and 603 (70%) had normal
23
24 haemoglobin concentration. Anemic patients were older, more likely to have
25
26 diabetes mellitus, hypertension, history of heart failure and chronic renal
27
28 impairment, HAS-BLED score ≥ 3 , higher CHA₂DS₂VASC score, and more
29
30 likely presented with acute coronary syndrome (ACS) as opposed to chronic
31
32 stable angina, compared with those without anemia ($p < 0.05$ for all), as shown
33
34 in Table 1. Furthermore, anemic patients had more vessels treated during the
35
36 index procedure, and a greater total stent length, compared with those without
37
38 anemia ($p < 0.05$ for both) (Table 2). At discharge, no significant differences
39
40 were seen in the prescription of antithrombotic medications in the two study
41
42 groups ($p = 0.15$) (Table 3). The duration of clopidogrel treatment did not differ
43
44 in anemic versus non-anemic patients on triple therapy (median [IQR]: 3 [11]
45
46 versus 3 [5] months, $p = 0.61$), on dual antiplatelet therapy (median [IQR]: 12
47
48
49
50
51
52
53
54
55
56
57
58
59
60

[11] versus 12 [11] months, $p=0.72$), or on vitamin K antagonist + clopidogrel (median [IQR]: 12 [11] versus 3 [11] months, $p=0.65$). Proton pump inhibitors were more frequently prescribed to patients with anemia versus those without (47.7 versus 31.3%, respectively, $p < 0.001$).

Table 1 Baseline clinical characteristics of the two study subgroups

Variable	Anemia (N=258)	Non-anemic (N=603)	<i>p</i> value
Age (yrs)	76 [9]	73 [11]	<0.001
Female gender	89 (34.5)	170 (28.2)	0.074
Diabetes mellitus	119 (46.1)	191 (31.7)	<0.001
Hypercholesterolemia	162 (62.8)	407 (67.5)	0.183
Current or ex-smoking	26 (10.1)	62 (10.3)	1.00
Hypertension	221 (85.7)	503 (83.4)	0.48
Paroxysmal atrial fibrillation	103 (39.9)	229 (38.0)	0.594
Persistent atrial fibrillation	22 (8.5)	78 (12.9)	0.081
Permanent atrial fibrillation	129 (50)	294 (48.8)	0.766

1				
2				
3				
4	CHA ₂ DS ₂ -VASc score >4	148 (57.4)	235 (39.0)	<0.001
5				
6	HAS BLED score ≥3	215 (83.3)	441 (73.1)	0.001
7				
8				
9	History of peptic ulcer	17 (6.6)	27 (4.5)	0.236
10				
11				
12	History of cerebral hemorrhage	4 (1.6)	6 (1.0)	0.497
13				
14				
15	History of GI hemorrhage	9 (3.5)	12 (2.0)	0.144
16				
17				
18	History of heart failure	69 (26.7)	113 (18.7)	0.011
19				
20				
21	eGFR below 60 ml/min	119 (52.2)	175 (31.9)	<0.001
22				
23				
24	Prior transient ischemic attacks	12 (4.7)	30 (5.0)	1.00
25				
26				
27				
28	Prior stroke	36 (14.0)	67 (11.1)	0.252
29				
30				
31	Prior MI	76 (29.5)	146 (24.2)	0.126
32				
33				
34	Prior PCI	47 (18.2)	100 (16.6)	0.555
35				
36				
37	Prior coronary bypass surgery	47 (18.2)	78 (12.9)	0.057
38				
39				
40	Proton pump inhibitors	123 (47.7)	189 (31.3)	<0.001
41				
42				
43	Stable angina pectoris	81 (31.4)	289 (48.0)	<0.001
44				
45				
46	ACS	177 (68.6)	313 (52.0)	<0.001
47				
48				
49	Unstable angina pectoris	53 (20.5)	107 (17.7)	0.34
50				
51				
52	Non-ST-elevation MI	83 (32.2)	132 (21.9)	0.002
53				
54				
55	ST-elevation MI	41 (15.9)	74 (12.3)	0.156
56				
57				
58				
59				
60				

Continuous variables are presented as median [interquartile range], whereas categorical variables are presented as frequency (percentage).

ACS indicates acute coronary syndrome; eGFR, estimated glomerular filtration rate; GI, gastrointestinal, IQR, inter-quartile range; MI, myocardial infarction; PCI, percutaneous coronary intervention.

Table 2 Procedural data of the two study subgroups

Variable	Anemia (N=258)	Non-anemic (N=603)	<i>p</i> value
Femoral access	196 (76.0)	435 (72.1)	0.275
Number of treated vessels	1.22 ± 0.45	1.15 ± 0.41	0.04
DES	67 (27.0)	138 (23.6)	0.293
Peri-procedural INR	1.9 [1]	1.88 [1]	0.509
Stent diameter (mm)	3 [1]	3 [1]	0.965
Total stent length (mm)	20 [18]	19 [14]	0.014
Procedural success	252 (97.7)	582 (96.5)	0.085
Hemostasis			
Manual compression	112 (43.4)	249 (41.3)	0.765
Compression device ^a	49 (19.0)	155 (25.7)	0.083
Access-site closure device ^b	82 (31.8)	165 (27.4)	0.154

Continuous variables are presented as mean \pm SD or median [interquartile range], whereas categorical variables are presented as frequency (percentage).

^aFemoStop[®], pneumatic compression device (Radi medical system, Sweden).

^bAngioseal[®], closure device (St. Jude medical, USA).

DES, drug-eluting stents; INR, international normalized ratio; IQR, inter-quartile range.

Table 3 Prescription of antithrombotic medications at discharge in the two study subgroups

Variable	Anemia (N=258)	Non-anemic (N=603)	<i>p</i> value
Triple therapy	181 (70.2)	442 (73.3)	0.15
DAPT	58 (22.5)	100 (16.6)	
VKA plus clopidogrel	15 (5.8)	51 (8.5)	
VKA plus aspirin	4 (1.6)	10 (1.7)	

Variables are presented as frequency (percentage).

VKA indicates vitamin K antagonist; DAPT, dual antiplatelet therapy.

Clinical outcome

Clinical outcomes at 12-month follow-up are presented in table 4 and figure 1.

The primary endpoint of MACCE was significantly more frequent in anemic patients than those without anemia (29.1 versus 19.4%, respectively, $p=0.002$).

This difference was driven by higher rates of all-cause mortality, non-fatal MI, and definite/probable ST ($p<0.05$ for all). Anemic patients had more BARC 3a bleeding events (7.0 versus 3.3%, respectively, $p=0.028$). No difference was

1
2
3 seen in BARC 5 bleedings. There was a trend toward more total bleeding
4
5 events (25.2% in anemic versus 21.7% in controls, $p=0.059$). (For detailed
6
7 information on bleeding events see [WebOnline](#) Table 2.) Total adverse events
8
9 occurred more frequently in anemic versus non-anemic patients (43.0 versus
10
11 31.5%, respectively, $p=0.001$).
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 4 Clinical outcome at 12-month follow-up in the two study subgroups

Endpoints	Anemia (N=258)	Non-anemic (N=603)	p value
MACCE	75 (29.1)	117 (19.4)	0.002
All-cause mortality	48 (18.6)	50 (8.3)	<0.001
Stroke/TIA	6 (2.3)	17 (2.8)	0.819
Peripheral arterial embolism	2 (0.8)	5 (0.8)	1.00
Non-fatal myocardial infarction	24 (9.3)	27 (4.5)	0.011
Any revascularization	19 (7.4)	51 (8.5)	0.683
Definite/probable stent thrombosis	10 (3.9)	4 (0.7)	0.002
Total bleeding events	65 (25.2)	131 (21.7)	0.059
Minor bleeding (BARC 2)	22 (8.5)	48 (8.0)	0.786
Major bleeding (BARC 3a, 3b, 3c, 5)	33 (12.8)	56 (9.3)	0.142
Access site complications	25 (9.7)	49 (8.1)	0.51
Pseudoaneurysm	7 (2.7)	18 (3.0)	1.0
Red blood cell transfusion	10 (3.9)	5 (0.9)	0.002
Need for corrective surgery	5 (1.9)	8 (1.3)	0.25
Prolonged hospitalization	15 (5.8)	23 (3.8)	0.21
Total adverse events	111 (43.0)	190 (31.5)	0.001

Variables are presented as frequency (percentage).

MACCE indicates major adverse cardiac and cerebrovascular events; TIA, transient ischemic attacks; BARC, Bleeding Academic Research Consortium.

1
2
3 The incidence of definite/probable stent thrombosis was significantly higher in
4
5 anemic versus non-anemic patients (3.9 versus 0.7%, respectively, $p=0.002$).
6
7
8 Patients who developed stent thrombosis more often presented with ACS than
9
10 those who did not (80.0 versus 56.6%, respectively, $p=0.07$); however, the use
11
12 of triple therapy did not differ statistically between groups (60.0 versus 73.3%,
13
14 respectively, $p=0.25$). Overall, nearly half (46.7%) of ST events occurred early
15
16 (<30 days). Acute (<24h after index PCI); early (<30 days) and late ST (>30
17
18 and < 365 days) were detected in 1 (0.4%) and 1 (0.2%) ($p=0.51$); 4 (1.6%) vs.
19
20 2 (0.3%) ($p=0.07$); and 6 (2.3%) vs. 2 (0.3%) ($p=0.01$) in patients with anemia
21
22 vs. those without anemia, respectively.
23
24
25
26
27
28
29
30
31

32 In univariate analysis age above 75, diabetes, congestive heart failure, anemia,
33
34 chronic renal impairment, ACS at presentation, and total stent length were
35
36 strongly correlated with both MACCE and all-cause mortality at 12-month
37
38 follow-up. In the Cox regression model including all the above variables,
39
40 independent predictors of all-cause mortality were anemia (HR 1.62, 95% CI
41
42 1.05 – 2.51, $p=0.029$), ACS at presentation (HR 2.26, 95% CI 1.37 – 3.75,
43
44 $p=0.001$), chronic renal impairment (HR 2.35, 95% CI 1.52 – 3.65, $p<0.001$),
45
46 and diabetes (HR 1.76, 95% CI 1.15 – 2.70, $p=0.009$). In contrast, anemia as a
47
48 categorical variable was not an independent predictor of MACCE at 12-months
49
50 follow-up unlike age above 75 years (HR 1.7, 95%-CI 1.2-2.4, $p=0.004$),
51
52
53
54
55
56
57
58
59
60

1
2
3 diabetes (HR 1.7, 95%-CI 1.2-2.3, p=0.002), ACS at presentation (HR 1.7,
4
5 95%-CI 1.2-2.3, p=0.003), and congestive heart failure (HR 1.5, 95%-CI 1.0-
6
7 2.1, p=0.03).

8
9
10 We performed the multivariate model also using haemoglobin as a continuous
11
12 variable. Independent predictors of all-cause mortality were pre-procedural
13
14 haemoglobin (HR 0.82, 95% CI 0.72 – 0.93, p=0.002), ACS at presentation
15
16 (HR 2.07, 95% CI 1.25 – 3.45, p=0.005), chronic renal impairment (HR 2.06,
17
18 95% CI 1.31 – 3.24, p=0.002), and diabetes (HR 1.75, 95% CI 1.14 – 2.70,
19
20 p=0.01) in a Cox regression model including age over 75 years, total stent
21
22 length and number of treated vessels as covariates. On the contrary to what
23
24 was found when assessing anemia as a categorical variable, haemoglobin as a
25
26 continuous variable predicted also MACCE. Independent predictors of
27
28 MACCE were pre-procedural haemoglobin (HR 0.89, 95% CI 0.81 – 0.98,
29
30 p=0.016), ACS at presentation (HR 1.55, 95% CI 1.10 – 2.18, p=0.012),
31
32 congestive heart failure (HR 1.45, 95% CI 1.03 – 2.04, p=0.035), age over 75
33
34 years (HR 1.77, 95%CI 1.27 – 2.45, p=0.001) and diabetes (HR 1.55, 95% CI
35
36 1.13 – 2.13, p=0.007) in a Cox regression model including also total stent
37
38 length, chronic renal impairment and number of treated vessels as covariates.
39
40
41
42
43
44
45
46
47
48
49

50 When the anemic patients were analysed separately in the Cox
51
52 regression model, age over 75 years and ACS at presentation were identified as
53
54 independent predictors of MACCE at 12-months; and chronic renal
55
56
57
58
59
60

1
2
3 impairment, age over 75 years and ACS at presentation as independent
4
5 predictors of all-cause mortality
6
7

8
9 Among 861 patients with available preprocedural measurement of
10
11 haemoglobin concentration, 26 (2.8%) had severe anemia (defined as
12
13 haemoglobin below 10 g/dl). In this subgroup, MACCE occurred in 12 (46.2%)
14
15 patients, 10 (38.5%) patients died, and 8 (30.8%) experienced a BARC 2-5
16
17 bleeding episode. At discharge, triple therapy was prescribed in 18 (69.2%)
18
19 patients, dual anti-platelet therapy in 8 (30.8%), and no patient was prescribed
20
21 vitamin K antagonists plus a single anti-platelet drug. Proton pump inhibitors
22
23 were prescribed at discharge in 18 (69.2%) patients, and one (3.8%) patient had
24
25 a history of gastrointestinal bleeding.
26
27
28
29
30
31
32
33
34

35 **DISCUSSION**

36
37 Our study is the first report on the impact of anemia on the long-term clinical
38
39 outcome of patients with AF undergoing PCI. The AFCAS registry represent a
40
41 real-life cohort of high-risk AF-patients requiring PCI. The results of the
42
43 current study showing that 30% of the patients were anemic confirm the
44
45 previous reports that anemia is a frequent finding in real-world patients with
46
47 AF referred for PCI.[6-9,14] Anemic patients in the AFCAS registry were older
48
49 with more comorbidities, and presented more often with ACS, compared with
50
51 non-anemic patients, as also reported in previous cohorts.[6,7,9,14].
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 Overall, the 12-month clinical outcome was worse in anemic patients. Anemia
7
8 remained an independent predictor of all-cause mortality in multivariate
9
10 analysis. The higher rate of all-cause mortality might be related to the higher-
11
12 risk profile in anemic patients, as well as the underlying disease causing
13
14 anemia. Furthermore, anemic patients had more frequent MACCE at 12
15
16 months, primarily driven by higher rates of all-cause mortality, and non-fatal
17
18 MI. However, anemia was not an independent predictor of MACCE. The higher
19
20 rate of non-fatal MI might be explained, at least in part, by the higher frequency
21
22 of ACS at presentation in anemic patients.
23
24
25
26
27
28
29
30
31

32 The estimated thromboembolic risk of anemic patients according to CHADS₂
33
34 score was higher. However, no excess in TIA or stroke was seen during the
35
36 follow-up and only a trend towards more bleeding was observed. This is
37
38 contradictory to previous studies which have reported a higher incidence of
39
40 cardiac and cerebrovascular thrombotic events at long-term follow-up in
41
42 anemic versus non-anemic patients in various patient cohorts referred for
43
44 PCI.[7,9,14-18] The relatively small number of complications in our patient
45
46 cohort might explain this difference.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The estimated bleeding risk according to the HAS-BLED score was higher in
4
5 anemic patients, but there was only a trend towards increased risk of major
6
7 bleeding. However, the results of the current study support the previous reports
8
9 on the increased bleeding risk associated with anemia in various patient groups
10
11 undergoing PCI.[8,9,19] Anemia may be a marker and consequence of an
12
13 underlying condition such as bleeding diathesis, occult gastrointestinal
14
15 bleeding, or malignancy that augments the bleeding risk. An interesting
16
17 observation is that neither the presence of anemia nor higher estimated bleeding
18
19 risk seemed to affect the clinician's choice of antithrombotic medications at
20
21 discharge. In view of our results, patients with anemia tolerated triple therapy
22
23 surprisingly well with only a trend towards increased bleeding.
24
25
26
27
28
29
30
31
32
33

34
35 We observed that the rate of definite or probable stent thrombosis was
36
37 significantly higher in anemic versus non-anemic patients ($p = 0.002$). ACS at
38
39 presentation may have contributed to the higher rate of stent thrombosis in
40
41 anemic patients, as patients with anemia more often presented with ACS versus
42
43 those without anemia. In addition, in individual cases the presence of anemia
44
45 may have influenced the choice of antithrombotic medication. Also, a bleeding
46
47 event could have lead to interruption of combination antithrombotic therapy
48
49 and thus to a higher risk of stent thrombosis. Consistent with our results,
50
51
52
53
54
55
56 Pilgrim and co-workers, observed a higher rate of definite stent thrombosis at
57
58
59
60

1
2
3 4-year follow-up in anemic patients who underwent PCI with unrestricted use
4
5 of drug-eluting stents, compared with non-anemic ones.[14] Interestingly, in a
6
7 recent study, anemia was the only independent predictor of high residual
8
9 platelet reactivity on clopidogrel in a series of patients undergoing PCI.[20]
10
11 These observations warrant further studies to clarify the underlying
12
13 mechanisms.
14
15
16
17
18
19
20

21
22 The effect of anemia on the clinical outcome of PCI appears early during
23
24 hospitalization. Kaplan-Meier event-free survival curves in the current study
25
26 revealed that most of the thrombotic as well as bleeding events occurred early
27
28 (within 30 days) following the index PCI (Figure 1). This finding is in line with
29
30 previous reports.[6,8,9,15] In patients with coronary artery disease, anemia
31
32 may aggravate myocardial ischemia, and unveil significant coronary
33
34 obstruction. Cardiac output increases in patients with anemia in order to
35
36 maintain adequate oxygen delivery to the tissues. This increases heart rate and
37
38 induces myocardial hypertrophy, which in turn, increases myocardial oxygen
39
40 demand, and further exaggerates the myocardial oxygen demand/supply
41
42 imbalance.[21] On the other hand, patients with severe anemia receive more
43
44 frequent blood transfusion, which was reported to have an adverse impact on
45
46 survival after PCI.[22] Unfortunately, information on blood transfusions was
47
48 not available in our registry except for the in-hospital phase. More importantly,
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 anemia is frequently associated with severe underlying chronic diseases which
4
5 may compromise long-term survival. Of note is a recent report suggesting that
6
7 in patients who underwent PCI with drug-eluting stents, those in whom anemia
8
9 improved at follow-up had less MACCE at a median follow-up of 25 months,
10
11 compared with those with sustained anemia suggesting that a transient cause is
12
13 less detrimental than a long-standing state causing anemia, e.g. malignancy.[16]
14
15
16
17
18
19
20

21 **Limitations of the study**

22
23
24 The current study has the inherent limitations of the observational study design,
25
26 including individual risk-based decision making in treatment choices, which
27
28 may introduce selection bias, even though we did not observe any difference
29
30 between the two study groups in the antithrombotic treatment prescribed at
31
32 discharge. Another possible confounder is the heterogeneity of the AF
33
34 population among the participating centers and some differences in the
35
36 periprocedural routines. Moreover, the aetiology of anemia was not
37
38 systematically investigated; yet, it is beyond the scope of the current study. The
39
40 strength of the study is the enrolment of consecutive patients with the only
41
42 exclusion criteria being unwillingness/inability to participate in the study. In
43
44 this sense the study population represents well real-world patients with AF
45
46 referred for PCI.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conclusion

Anemia was a frequent finding in patients with AF referred for PCI. ~~Anemic patients were older with more frequent comorbidities, and more often presented with ACS.~~ Anemia seems to be an independent risk factor for all-cause mortality during 12-month follow-up. Anemia is also associated with more MACCE, and a trend toward a higher rate of bleeding.

ACKNOWLEDGMENTS

We thank our study coordinator Tuija Vasankari, RN, for her valuable input in data management.

COMPETING INTERESTS

The authors declare no competing interests.

FUNDING

This study was supported by grants from the Finnish Foundation for Cardiovascular Research, Helsinki, Finland.

REFERENCES

1. Rubboli A, Halperin JL, Airaksinen KE, et al. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. *Ann Med* 2008;40(6):428-36.
2. Rubboli A, Colletta M, Valencia J, et al for the WARfarin, Coronary STENTing (WAR-STENT) Study Group. Periprocedural management and in-hospital outcome of patients with indication for oral anticoagulation undergoing coronary artery stenting. *J Interv Cardiol* 2009;22:390–397.
3. Lip GYH, Huber K, Andreotti F, et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary—a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J* 2010;31:1311-1318.
4. Faxon DP, Eikelboom JW, Berger PB, et al. Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. *Thromb Haemost* 2011;106:522-84.

- 1
2
3 5. Rubboli A, Dewilde W, Huber K, et al. The management of patients on oral
4
5 anticoagulation undergoing coronary stent implantation: a survey among
6
7 interventional cardiologists from eight European countries. *J Interv Cardiol*
8
9 2012;25:163-9.
10
- 11
12
13 6. McKechnie RS, Smith D, Montoye C, et al; Blue Cross Blue Shield of
14
15 Michigan Cardiovascular Consortium (BMC2). Prognostic implication of
16
17 anemia on in-hospital outcomes after percutaneous coronary intervention.
18
19 *Circulation* 2004;110(3):271-7.
20
21
- 22
23
24 7. Nikolsky E, Mehran R, Aymong ED, et al. Impact of anemia on outcomes of
25
26 patients undergoing percutaneous coronary interventions. *Am J Cardiol*
27
28 2004;94(8):1023-7.
29
30
- 31
32
33 8. Dündar C, Oduncu V, Erkol A, et al. In-hospital prognostic value of
34
35 hemoglobin levels on admission in patients with acute ST segment elevation
36
37 myocardial infarction undergoing primary angioplasty. *Clin Res Cardiol*
38
39 2012;101(1):37-44.
40
41
- 42
43
44 9. Ayhan E, Aycicek F, Uyarel H, et al. Patients with anemia on admission
45
46 who have undergone primary angioplasty for ST elevation myocardial
47
48 infarction: in-hospital and long-term clinical outcomes. *Coron Artery Dis*
49
50 2011;22(6):375-9.
51
52
53
54
55
56
57
58
59
60

- 1
2
3 10. Kiviniemi T, Karjalainen P, Rubboli A, et al. Thrombocytopenia in patients
4
5 with atrial fibrillation on oral anticoagulation undergoing percutaneous
6
7 coronary intervention. *Am J Cardiol* 2013 Aug 15;112(4):493-8.
8
9
- 10
11 11. Schlitt A, Rubboli A, Lip GY, et al; for the AFCAS (Management of
12
13 patients with Atrial Fibrillation undergoing Coronary Artery Stenting Study
14
15 Group). The management of patients with atrial fibrillation undergoing
16
17 percutaneous coronary intervention with stent implantation: In-hospital-data
18
19 from the atrial fibrillation undergoing coronary artery stenting study.
20
21 *Catheter Cardiovasc Interv* 2013;82(7):E864-70
22
23
- 24
25 12. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for
26
27 cardiovascular clinical trials: a consensus report from the bleeding academic
28
29 research consortium, *Circulation* 2011;123:2736-2747.
30
31
32
- 33
34 13. Nutritional anaemias. Report of a WHO scientific group. *World Health*
35
36 *Organ Tech* 1968;405:5–32.
37
38
- 39
40 14. Pilgrim T, Vetterli F, Kalesan B, et al. The impact of anemia on long-term
41
42 clinical outcome in patients undergoing revascularization with the
43
44 unrestricted use of drug-eluting stents. *Circ Cardiovasc Interv.*
45
46 2012;5(2):202-10.
47
48
- 49
50 15. Lee PC, Kini AS, Ahsan C, et al. Anemia is an independent predictor of
51
52 mortality after percutaneous coronary intervention. *J Am Coll Cardiol*
53
54 2004;44(3):541-6.
55
56
57
58
59
60

- 1
2
3 16.Kim TH, Koh YS, Chang K, et al; CathOlic university of Korea –
4
5 percutAneous Coronary inTervention registry investigators. Improved
6
7 anemia is associated with favorable long-term clinical outcomes in patients
8
9 undergoing PCI. *Coron Artery Dis* 2012;23(6):391-9.
10
11
12
13 17.Kitai Y, Ozasa N, Morimoto T, et al; on behalf of the CREDO-Kyoto
14
15 registry investigators. Prognostic implications of anemia with or without
16
17 chronic kidney disease in patients undergoing elective percutaneous
18
19 coronary intervention. *Int J Cardiol* 2013;168(6):5221-8.
20
21
22
23 18.Hosseini SK, Ansari MJ, Lotfi Tokaldany M, et al. Association between
24
25 preprocedural hemoglobin level and 1-year outcome of elective
26
27 percutaneous coronary intervention. *J Cardiovasc Med.* 2013 Feb 15. [Epub
28
29 ahead of print]
30
31
32
33 19.Manzano-Fernández S, Pastor FJ, Marín F, et al. Increased major bleeding
34
35 complications related to triple antithrombotic therapy usage in patients with
36
37 atrial fibrillation undergoing percutaneous coronary artery stenting. *Chest*
38
39 2008;134(3):559-67.
40
41
42
43 20.Toma C, Zahr F, Moguilanski D, et al. Impact of anemia on platelet
44
45 response to clopidogrel in patients undergoing percutaneous coronary
46
47 stenting. *Am J Cardiol* 2012;109(8):1148-53.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 21.Foley RN, Parfrey PS, Hamett JD, et al. The impact of anemia on
4
5 cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J
6
7 Kidney Dis 1996;28:53– 61.
8
9

10
11 22.Maluenda G, Lemesle G, Ben-Dor I, et al. Value of blood transfusion in
12
13 patients with a blood hematocrit of 24% to 30% after percutaneous coronary
14
15 intervention. Am J Cardiol 2009;104:1069 –1073.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FIGURE LEGENDS

Figure 1 Kaplan-Meier survival curves for the occurrence of adverse events in anemic (dotted lines) versus non-anemic (solid line) patients at 2-month follow-up: all-cause mortality (a), MACCE free survival (b) and bleeding event free survival (c)

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract ok (b) Provide in the abstract an informative and balanced summary of what was done and what was found ok
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported ok
Objectives	3	State specific objectives, including any prespecified hypotheses ok
Methods		
Study design	4	Present key elements of study design early in the paper ok
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection ok
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up ok (b) For matched studies, give matching criteria and number of exposed and unexposed
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable ok
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why ok
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding ok (b) Describe any methods used to examine subgroups and interactions ok (c) Explain how missing data were addressed ok (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed ok (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders ok (b) Indicate number of participants with missing data for each variable of interest ok (c) Summarise follow-up time (eg, average and total amount) ok
Outcome data	15*	Report numbers of outcome events or summary measures over time ok
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included ok

		(b) Report category boundaries when continuous variables were categorized ok
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses ok
Discussion		
Key results	18	Summarise key results with reference to study objectives ok
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias ok
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence ok
Generalisability	21	Discuss the generalisability (external validity) of the study results ok
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based ok

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.